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ABSTRACT
Technological and scientific advances in recent years have revolutionized genomics. For example,
decreases in whole genome sequencing (WGS) costs have enabled largerWGS studies as well as larger
imputation reference panels, which in turn provide more comprehensive genomic coverage from
lower-cost genotyping methods. In addition, new technologies and large collaborative efforts such
as ENCODE and GTEx have shed new light on regulatory genomics and the function of non-coding
variation, and produced expansive publicly available data sets. These advances have introduced data
of unprecedented size and dimension, unique statistical and computational challenges, and numerous
opportunities for innovation. In this dissertation, we develop methods to leverage functional
genomics data in post-GWAS analysis, to expedite routine computations with increasingly large
genetic data sets, and to address limitations of current imputation reference panels for understudied
populations.
In Chapter 2, we propose strategies to improve imputation and increase power in GWAS of
understudied populations. Genotype imputation is instrumental in GWAS, providing increased
genomic coverage from low-cost genotyping arrays. Imputation quality depends crucially on
reference panel size and the genetic distance between reference and target haplotypes. Current
reference panels provide excellent imputation quality in many European populations, but lower
quality in non-European, admixed, and isolate populations. We consider a GWAS strategy in
which a subset of participants is sequenced and the rest are imputed using a reference panel that
xi
comprises the sequenced participants together with individuals from an external reference panel.
Using empirical data from the HRC and TOPMedWGS Project, simulations, and asymptotic analysis,
we identify powerful and cost-effective study designs for GWAS of non-European, admixed, and
isolated populations.
In Chapter 3, we develop efficient methods to estimate linkage disequilibrium (LD) with large
data sets. Motivated by practical and logistical constraints, a variety of statistical methods and tools
have been developed for analysis of GWAS summary statistics rather than individual-level data. These
methods often rely on LD estimates from an external reference panel, which are ideally calculated
on-the-fly rather than precomputed and stored. We develop efficient algorithms to estimate LD
exploiting sparsity and haplotype structure and implement our methods in an open-source C++
tool, emeraLD. We benchmark performance using genotype data from the 1KGP, HRC, and UK
Biobank, and find that emeraLD is up to two orders of magnitude faster than existing tools while
using comparable or less memory.
In Chapter 4, we develop methods to identify causative genes and biological mechanisms
underlying associations in post-GWAS analysis by leveraging regulatory and functional genomics
databases. Many gene-based association tests can be viewed as instrumental variable methods in
which intermediate phenotypes, e.g. tissue-specific expression or protein alteration, are hypothesized
to mediate the association between genotype and GWAS trait. However, LD and pleiotropy
can confound these statistics, which complicates their mechanistic interpretation. We develop a
hierarchical Bayesianmodel that accounts formultiple potential mechanisms underlying associations
using functional genomic annotations derived from GTEx, Roadmap/ENCODE, and other sources.
We apply ourmethod to analyze twenty-five complex traits using GWAS summary statistics fromUK
Biobank, and provide an open-source implementation of our methods.
In Chapter 5, we review our work, discuss its relevance and prospects as new resources emerge,
xii
and suggest directions for future research.
xiii
Chapter 1
Introduction
1.1 Background
The past two decades have seen an explosion of technological and scientific advances in genomics.
As new sequencing technologies have emerged, the cost of whole-genome sequencing (WGS) has
fallen from over $100M USD to under $1,000 USD per genome (KA 2018), enabling larger WGS
studies as well as larger haplotype reference panels (e.g., McCarthy et al. 2016), which in turn
provide more comprehensive genomic coverage from lower-cost genotyping methods through
genotype imputation. New technologies and large collaborative efforts such as the Encyclopedia
of DNA Elements (ENCODE) project, NIH Roadmap Epigenomics Mapping Consortium, and
Genotype-Tissue Expression (GTEx) project have produced a wealth of data and shed new light
on regulatory genomics and the functional non-coding genome (ENCODE Project Consortium
2012; GTEx Consortium 2015; Karczewski and Snyder 2018). Genome-wide association studies
(GWAS) have identified thousands of genetic variants associated with hundreds of complex traits
(MacArthur et al. 2016), and while the biological mechanisms underlying these associations are often
poorly understood, there have been notable breakthroughs in genomic medicine and gene therapy
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(e.g., Ribeil et al. 2017; Rangarajan et al. 2017). Altogether, these advances have produced data of
various new types and unprecedented volume, presenting new challenges as well as opportunities
for statistical innovation.
Challenges & Opportunities from Advances in Genomics
Large sequencing studies and imputation reference panels, made possible by advances in sequencing
technologies, require enormous computational resources to process, store, and analyze, presenting a
need for more efficient data formats and analysis methods (McCarthy et al. 2016; Das et al. 2016).
In addition, large reference panels have enabled far more accurate and comprehensive genotype
imputation for many populations, prompting a need to re-assess the relative cost-effectiveness
of sequencing and imputation-based genotyping in GWAS, and to develop more powerful and
cost-effective genotyping strategies for understudied populations (McCarthy et al. 2016; B. Li and
Leal 2008). Large omics studies, empowered by new experimental techniques as well as sequencing
technologies, have constructed expansive databases characterizing transcriptomic, proteomic, and
metabolomic interactions as well as the functional effects of coding and non-coding variation
(ENCODE Project Consortium 2012; GTEx Consortium 2015; De Rie et al. 2017). These data,
together with more comprehensive genomic coverage in GWAS, can provide more refined insights
into the biological pathways that underlie genetic effects on complex traits, prompting a need for
statistical methods to integrate GWAS with diverse types of functional genomic data.
Purpose
In this dissertation, we develop statistical methods to leverage functional genomics databases in
post-GWAS analysis, to expedite routine computations with increasingly large genetic data sets, and
to address limitations of current imputation reference panels for understudied populations.
2
1.2 Genotype Imputation: Challenges for Understudied
Populations
Genotype imputation has been instrumental in GWAS, enabling more complete meta-analysis of
results frommultiple studies, and providing increased genomic coverage from array-based genotype
callsets (Y. Li et al. 2009). Imputation algorithms typically employ a Hidden Markov Model (HMM)
in which partially observed haplotypes in the study sample are modeled as mosaics of complete
haplotypes in a reference panel (N. Li and Stephens 2003; e.g., International HapMap 3 Consortium
2010; 1KGP Consortium 2015). Genotyping arrays, e.g. the Illumina OmniExpress, are often used
to construct a scaffold for imputation via array-based genotype calls over a sparse set of directly
typed marker variants. This array-and-imputation genotyping strategy provides an inexpensive in
silico alternative to whole genome sequencing, the gold-standardmethod to capture genetic variation
comprehensively across the allele frequency spectrum.
Imputation coverage and accuracy depend crucially on the genetic similarity between reference
and target populations (Roshyara and Scholz 2015) and the number of reference haplotypes available
(Das et al. 2016). The earliest imputation reference panels, e.g. from the 1000 Genomes Project
and International HapMap Consortium, included individuals from diverse worldwide human
populations (1KGP Consortium 2015; International HapMap 3 Consortium 2010). These projects
provided new insights into haplotype structure and demographic history across human populations,
as well as new resources for genotype imputation. By contrast, the largest current imputation
reference panels, e.g. from the Haplotype Reference Consortium (HRC; McCarthy et al. 2016) and
UK10K Consortium (UK10K Consortium 2015), are largely European. These reference panels have
enabled far more accurate and comprehensive imputation for many European populations, but are
less effective for non-European, admixed, and isolate populations (UK10K Consortium 2015). In
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populations that are underrepresented in current imputation reference panels, population-matched
or multi-ethnic reference panels can be constructed to provide improved imputation quality (Deelen
et al. 2014; Lencz et al. 2017; Ahmad et al. 2017).
In Chapter 2, we propose strategies to improve genotype imputation and increase power in
GWAS of diverse human populations. We consider a strategy in which a subset of participants is
sequenced and the rest are imputed using a reference panel that comprises the sequenced participants
together with individuals from an external reference panel. Using empirical data from the Haplotype
Reference Consortium (HRC) and NHLBI Trans-Omics for Precision Medicine (TOPMed) Whole
Genome Sequencing (WGS) Project, simulations, and asymptotic analysis, we identify powerful and
cost-effective sequencing-and-imputation study designs for GWAS of non-European, admixed, and
isolated populations.
1.3 Leveraging Natural Features of Genetic Data to Expedite
Computation
Demographic history and the driving processes of mutation and recombination impart distinctive
features to human genetic datasets. For example, the mutation process coupled with explosive
population growth produces an abundance of rare variant alleles, resulting in natural sparsity (Kimura
1983; Takahata 1996; Keinan and A. G. Clark 2012); and the sharing of short genomic segments
between unrelated individuals produces a high degree of redundancy (Wall and Pritchard 2003;
International HapMap 3 Consortium 2010). In Chapter 3, we leverage these properties to expedite
linkage disequilibrium estimation with large data sets.
Linkage disequilibrium (LD) refers to association between alleles at different genetic variants,
which generally decays with increasing distance between variants on a given chromosome due to
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genetic recombination. Accounting for LD is critical for many multi-variant genetic association
methods, e.g. conditional analysis and fine-mapping (Benner et al. 2016; Wen et al. 2016; Lee et al.
2018), gene-based association (Lamparter et al. 2016; Bakshi et al. 2016; Feng et al. 2014), and
functional enrichment analysis (Finucane et al. 2015; Lamparter et al. 2016). These methods are often
applied to GWAS summary association statistics (single-variant test statistics, or effect size estimates
and standard errors), and rely on LD estimates that are pre-computed from the GWAS sample (e.g.,
Feng et al. 2014) or estimated from an external population-matched reference panel (e.g., Lamparter
et al. 2016). Existing tools to estimate LD often scale linearly with sample size, prompting a need for
more efficient methods for increasingly large genetic data sets. In Chapter 3, we develop efficient
algorithms to estimate LD exploiting sparsity and haplotype structure. We implement our methods
in an open-source C++ tool, emeraLD, which is up to two orders of magnitude faster than existing
tools while using comparable or less memory.
1.4 Leveraging Prior Knowledge from Functional Genomics
Studies for Informative, Comprehensive Gene-Based
Analysis
New technologies and large collaborative projects in recent years have produced extensive datasets
characterizing functional elements throughout the human genome and regulatory effects of
non-coding genetic variation. For example, the NIH Roadmap Epigenomics Mapping Consortium
has used next-generation sequencing technologies to produce epigenomic datasets across a number
of human tissues and cell types (Kundaje et al. 2015); the Encyclopedia of DNA Elements (ENCODE)
project has characterized functional elements throughout the human genome across a variety of
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tissues and cell types using ChiP-seq, Methyl-seq, RNA-seq and other techniques (Kellis et al.
2014); the Genotype-Tissue Expression (GTEx) project has produced transcriptomic and eQTL
mapping datasets across 49 human tissues (GTEx Consortium 2015); and the FANTOM (Functional
ANnoTation Of the Mammalian genome) consortium has used RNA sequencing and Cap Analysis
of Gene Expression (CAGE) to characterize active enhancers and promoters across a wide range
of human and mouse cell types (De Rie et al. 2017). These projects have greatly enhanced our
understanding of regulatory genomics and functional non-coding variation, and have enabled new
insights into the mechanisms underlying non-coding GWAS associations.
Integrating functional genomic annotations with GWAS data has been an active area of
methodological research (e.g., Gusev et al. 2016; Hao et al. 2018; Wu et al. 2018). For example,
stratified LD score regression (S-LDSC) and SMART have been applied to partition complex trait
heritability across functional elements and detect functional enrichment using annotations from
ENCODE, Roadmap, and other sources (Finucane et al. 2015; Hao et al. 2018). Methods such as
TWAS and PrediXcan use predictive weights estimated from eQTL mapping datasets (e.g., from
GTEx) to assess associations between complex traits and the genetic component of gene expression
levels (Gamazon et al. 2015; Gusev et al. 2016). Similarly, the SMR (summary-data-based Mendelian
randomization) and HEIDI (heterogeneity in dependent instruments) methods have been applied
to assess gene regulatory perturbations underlying GWAS associations using eQTL and mQTL
datasets (Wu et al. 2018). Finally, Bayesian finemapping methods have been developed incorporating
functional genomic annotations to help prioritize causal variants and assess mechanisms underlying
associations (Kichaev, Yang, et al. 2014; Kichaev and Pasaniuc 2015; Wen et al. 2016).
In Chapter 4, we present GaMBIT, a unified statistical framework to infer causative genes,
pathways, and biological mechanisms underlying GWAS associations leveraging diverse functional
annotations. Our approach accounts for multiple potential mechanisms underlying GWAS
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associations to avoid spurious inferences caused by pleiotropy and LD, and leverages trait-specific
patterns of functional enrichment to improve prioritization of causal genes and mechanisms. We
discuss relationships between the proposed model and existing gene-based tests and fine-mapping
methods, and demonstrate that GaMBIT improves prioritization of causal genes and mechanisms
through simulation studies. Finally, we apply our method to analyze twenty-five complex traits
using GWAS summary statistics from the UK Biobank resource, and provide an open-source
implementation of our methods.
1.5 Looking Forward
Human genomics is a rapidly evolving field, and the emergence of new technologies, studies, and data
resources present new statistical and computational challenges. In Chapter 5, we review our work
and discuss future prospects and opportunities as new resources emerge.
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Chapter 2
Sequencing and Imputation in GWAS: Cost-Effective Strategies
to Increase Power and Genomic Coverage Across Populations
2.1 Introduction
Genome-wide association studies (GWAS) have detected thousands of common genetic variants
associated with hundreds of complex diseases and traits (MacArthur et al. 2016). A key aim for
the next wave of GWAS is to interrogate the full spectrum of genetic variation underlying human
genetic traits, including rare (minor allele frequency [MAF] ≤ 0.5%) variants. Detecting association
at rare variants requires bothmore comprehensive genomic coverage and sufficient sample size. Deep
whole genome sequencing (WGS) is the gold standard method for capturing rare variation; however,
even in the era of the $1,000 genome, large WGS association studies remain prohibitively expensive.
Genotype imputation has been a mainstay of GWAS, providing increased genomic coverage from
inexpensive array-based genotype call sets. While initial imputation studies only surveyed common
variants (e.g., Scott et al. 2007), larger and more diverse reference panels now enable more accurate
and comprehensive imputation of rare and low-frequency variants across awide range of populations
(e.g., Mahajan et al. 2018).
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Imputation algorithms model haplotypes in the study sample as mosaics of haplotypes in a
reference panel (e.g. from the International HapMap Project [International HapMap 3 Consortium
2010] or 1000 Genomes Project [1KGP Consortium 2015]) to predict genotypes at untyped variants
(Li et al. 2009). By increasing genomic coverage and accuracy, imputation increases statistical power
to detect association, enables more complete meta-analysis of results from multiple studies, and
facilitates the identification of causal variants through fine-mapping (Li et al. 2009; Das et al. 2016).
Imputation coverage and accuracy depend crucially on the size of the reference panel and the genetic
distance between reference and target populations (Li et al. 2009; Roshyara and Scholz 2015). The
largest current broadly available reference panels, e.g. from the Haplotype Reference Consortium
(S. McCarthy et al. 2016) (HRC) and UK10K project (UK10K Consortium 2015), include tens of
thousands of predominantly European individuals. These panels provide near complete imputation
of genetic variation down to MAF=0.1% for many European populations, but lower imputation
quality for non-European and admixed populations and population isolates, particularly for rare and
low-frequency (0.5%<MAF < 5%) variants (Deelen et al. 2014; Pistis et al. 2015; Zhou et al. 2017). The
1000 Genomes Project and HapMap panels include individuals from diverse worldwide populations,
but provide more limited imputation coverage and accuracy due to their smaller sample sizes.
Capturing rare variation across diverse populations is crucial to detect population differences
in genetic risk factors, accurately predict genetic risk, and identify causal variants and biological
mechanisms through trans-ethnic fine-mapping (Kichaev and Pasaniuc 2015; Popejoy and Fullerton
2016). Population-matched or multi-ethnic reference panels can improve imputation quality and
coverage for rare variants in GWAS of diverse populations (Deelen et al. 2014; Pistis et al. 2015; Zhou
et al. 2017; Ahmad et al. 2017; Lencz et al. 2017; Van Leeuwen et al. 2015); this approach has enabled
discovery of novel loci and refinement of association signals for multiple populations and complex
traits (Pistis et al. 2015; Auer and Lettre 2015; Holm et al. 2011).
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Here, we consider an approach inwhich a subset of study participants is whole genome sequenced
and the rest are array-genotyped and imputed using an augmented reference panel that comprises
the sequenced participants and individuals from an external reference panel (Hu et al. 2015; Zeggini
2011). This hybrid sequencing-and-imputation strategy providesmore comprehensive coverage than
only array genotyping, and is less costly than whole genome sequencing the entire sample. We
and others have used this strategy (Van Leeuwen et al. 2015; Fuchsberger et al. 2016; Sidore et al.
2015; Steinthorsdottir et al. 2014), but no analysis of coverage, power, and cost-effectiveness has
been carried out to date. Here, we assess how imputation coverage and power to detect association
vary across genotyping arrays and as a functions of the number of population-matched individuals
sequenced and included in the reference panel for two admixed populations (African Americans
and Latino Americans) and two European population isolates (Sardinians and Finns) to identify
powerful and cost-effective strategies for GWAS in these populations. We also describe an interactive
web-based tool to assist researchers in the design and planning of their own GWAS.
Figure 2.1.1: Sequencing-and-Imputation GWAS Flowchart
GWAS
Array Data
Imputed GWAS
Array Data
External 
Reference 
Panel
Augmented 
Reference Panel
GWAS 
Sequence Data
Association
Analysis
Flowchart of sequencing and imputation GWAS strategy. An augmented reference panel that comprises sequenced
GWAS participants and an external panel is used to impute array-genotyped GWAS samples. Both sequenced and
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imputed GWAS participants are included in association analysis.
2.2 Materials and Methods
We first describe WGS data sources used in our analysis. Next, we describe imputation strategies,
and outline procedures and imputation quality metrics to compare these strategies. Finally,
we present a novel method to estimate power for the sequencing-only, imputation-only, and
sequencing-and-imputation strategies. For ease of presentation, we assume a dichotomous trait and
a multiplicative disease model, although our findings generalize easily to continuous traits and other
genetic models.
2.2.1 Data Resources
WeusedWGS data on 3,412 African Americans (participants from the JacksonHeart Study) and 2,068
Latino Americans (participants of Puerto Rican and Mexican descent from the GALA II study and
Costa Rican descent from the Genetic Epidemiology of Asthma in Costa Rica and CAMP studies)
in the National Heart, Lung, and Blood Institute (NHLBI) Trans-Omics for Precision Medicine
(TOPMed) WGS program, and on 2,995 Finns (participants of the GoT2D, 1KGP, SISu, and Kuusamo
studies) and 3,445 Sardinians (participants of the SardiNIA study) in the HRC to compare imputation
quality between reference panel configurations and genotyping arrays.
2.2.2 Procedures to Evaluate Imputation Coverage and Accuracy
We considered three imputation strategies: (1) using sequenced study participants as a study-specific
reference panel, (2) using an external reference panel alone (for this comparison, the HRC or HRC
subset excluding individuals from the target population), and (3) using an augmented panel that
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comprises sequenced study participants and an external panel.
For African Americans, which are underrepresented in the current version 1.1 of the HRC,
we constructed population-specific and HRC-augmented reference panels with 0 to 2,000 African
Americans. For Latino Americans, we used the same approach but restricted the study-specific panel
size to <1,500 due to the more limited available sample of sequenced Latino American individuals.
For Finns and Sardinians, which are present in the HRC, we constructed augmented reference panels
that comprised the 29,470 non-Finnish or 29,020 non-Sardinian individuals in the HRC together
with 0 to 2,000 Finns or Sardinians from the HRC.
For each population, each imputation strategy, and each of three commonly-used genotyping
arrays (Table 2.1), we used sequence-based genotype calls at marker variants present on the array
as a scaffold for imputation using Minimac3, masking the remaining sequence-based genotype calls
(Das et al. 2016). We then compared the imputed genotype dosages to the true (masked) genotypes
to estimate (a) imputation r2, the squared Pearson correlation between true genotype and imputed
dosage, and (b) imputation coverage, the proportion of variants with imputation r2 ≥ 0.3 and minor
allele count (MAC) ≥ 5 (the MAC threshold used by the HRC panel [S. McCarthy et al. 2016]) in the
reference panel.
Table 2.1: Genotyping Arrays Used for Comparisons
Array No. Marker Variants List Cost per Sample (Illumina Inc. 2018)
Illumina Infinium Core 307K $49
Illumina Infinium OmniExpress 710K $94
Illumina Infinium Omni2.5 2.5M $172
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2.2.3 Estimating Power to Detect Association using Empirical Imputation
Quality Data
When sequenced individuals are included in the reference panel, power calculations should account
for the interdependence between imputation r2 and the number of participants sequenced n, and for
the possibility that the variant is not imputable (absent in the reference panel or not imputed due to
insufficient MAC, or filtered prior to association analysis due to imputation r2 falling below a given
threshold). While common variant associations are likely to be captured by LD proxy SNPs even
when the causal variant is not directly genotyped or imputed, rare variant associations are much less
likely to be captured by proxy SNPs (Montpetit et al. 2006). Here, we assume that power to detect
association for variants that are not imputable is zero. This assumption affects power calculations
almost exclusively for rare variants, since common variants are almost uniformly imputable with
large reference panels (Das et al. 2016; S. McCarthy et al. 2016).
We assume that the n participants who are sequenced are randomly subsampled from the overall
sample of n+m study participants, and that test statistics are calculated separately for the sequenced
and imputed subsamples and combined using the effective sample size weighted meta-analysis test
statisticZnm = c
1/2
nmZseqn +(1−cnm)1/2Z impm , where cnm = n/(n+r2m). The asymptotic distribution
of Znm − η
√
n+ r2m is normal with mean 0 and variance 1, where r2 is the squared correlation
between imputed dosages and true genotypes, and η is an effect size parameter which is equal to
0 under the null hypothesis of no association. The form of η depends on the association model
(additive, dominant, multiplicative), relative risk or odds ratio, MAF, and population prevalence and
case-control ratio for binary traits. Under an arbitrary association model for binary traits, we can
write
16
η =
2(pcase − pcontrol)√
(1 + s)
(
vcase +
1
s
vcontrol
)
+ 4 (pcase − pcontrol)2
where pcase and pcontrol are the alternate allele frequencies in the disease-positive and disease-negative
populations, vcase and vcontrol are the variances of genotypes in the disease-positive and
disease-negative populations, and s is the GWAS case-control ratio.
To estimate power while accounting for variability in imputation r2 and the possibility that a
variant is not imputable, we average empirical imputation r2 values and MACs across variants from
experimentswith real data described in the previous section. Specifically, we estimate power to detect
association when n individuals are sequenced andm are genotyped and imputed as
ˆPower(m,n) =
1∑
j wj
∑
j
wjCnj
∫ z1−α/2
−z1−α/2
φ
(
u− η
√
n+ r2njm
)
du
where φ (u) = e−
u2
2 /
√
2pi is the standard normal density function, z1−α/2 is the α-level significance
threshold, r2nj is the imputation r2 value for the jth variant,Cnj = I(MAC
panel
nj ≥ 5, r2nj ≥ 0.3) is an
indicator equal to 1 if the jth variant was imputable and 0 otherwise, andMACpanelnj is the reference
panel MAC for the jth variant when the n sequenced individuals from the target population were
included in the reference panel.
We define the weightswj = PGWASN (pˆj)/PˆN(pˆj), whereN is the total number of samples used in
our analysis for the given population (e.g. N =3,412 for African Americans), pˆj is the sampleMAF for
the jth variant in the total sample, PˆN(x) is the proportion of variants with MAF = x, and PGWASN (x)
is the probability of observing sample MAF = x in a sample of sizeN given the specified association
model. For example, in a GWAS with sample size N and case-control ratio s, the sample MAC
(which is equal to 2Npˆ, where pˆ is the sample MAF) is approximately Poisson distributed with mean
2N(spcase+pcontrol)/(s+1), where pcase = pγ/(1+p(γ−1)) and pcontrol = (p−Kpcase)/(1−K) for
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a variant with population MAF p and relative risk γ for a disease with prevalenceK . This weighting
approach adjusts for differences between the empirical distribution of MACs across variants in real
data, and the theoreticalMACdistribution for a variantwith the specifiedMAF, effect size, prevalence
in a GWAS with sample sizeN and case-control ratio s.
2.3 Results
First, we compare strategies to improve imputation using study-specific WGS data for African
Americans, Latino Americans, Sardinians, and Finns. Next, we assess the effects of genotyping array
on imputation quality and coverage for each population and reference panel. We then use these
results to estimate statistical power to detect association as a function of study-specific panel size,
number of participants imputed, external reference panel, and genotyping array. Finally, we identify
cost-effective study designs by comparing statistical power and total experimental (sequencing and
genotyping) costs for sequencing-only, imputation-only, and sequencing-and-imputation GWAS
designs for each population and genotyping array.
2.3.1 Strategies to Improve Imputation using Study-Specific WGS Data
We compared imputation r2 and coverage (proportion of variants with imputation r2>0.3 and
reference MAC ≥ 5) for three imputation strategies: (1) using an external panel (the HRC or HRC
subset) alone, (2) using an augmented panel that combines the study-specific and external panels, and
(3) using a study-specific panel alone.
The external panel alone (HRC for Latino Americans andAfrican Americans, andHRC subset that
excludes individuals from the target population for Finns and Sardinians) provided 96% imputation
coverage for MAF ≥ 0.25% variants (where MAF is calculated separately within each population)
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for Finns, 84% coverage for Sardinians, 86% coverage for Latino Americans, and 77% coverage for
African Americans (Figure 2.3.1A). The relatively lower coverage for African Americans is expected
since the HRC consists primarily of Central and Northern Europeans, who are genetically closer to
Finns and Sardinians, and includes relatively few Africans or African Americans. Despite the small
number of Latino or Native Americans included in the HRC, imputation coverage was slightly higher
for Latino Americans than for Sardinians. This may reflect the high degree of European admixture in
many Latino American populations (Bryc et al. 2010), and the abundance of population-specific rare
and low-frequency variants in the Sardinian population (Sidore et al. 2015).
Figure 2.3.1: Imputation Quality by Population and Genotyping Array.
Imputation and coverage as a function of number of population-matched individuals included in augmented reference
panels (Number Sequenced). Here and elsewhere, MAF is calculated separately within each population.
Augmenting an external reference panel with even a relatively small number of sequenced
individuals substantially increased coverage, particularly for African Americans and Sardinians and
for variants with lower MAF. For example, augmenting the external panel with 500 sequenced
individuals from the study population improved overall imputation coverage for MAF=0.25-0.5%
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variants by 4% for Finns, 9% for LatinoAmericans, 16% forAfricanAmericans, and 23% for Sardinians
genotyped using the OmniExpress relative to the external panel alone (Figure 2.3.1A). Similarly,
augmenting the external reference panel with even 200 individuals increased imputation coverage
for =0.1-0.25% variants by 3%, 4%, 6%, 10% relative to the external panel alone for Finns, Latino
Americans, African Americans, and Sardinians, respectively.
With 2,000 individuals from the target population (or 1,500 for Latino Americans),
population-specific panels provided roughly equivalent imputation r2 compared to augmented
panels (Supplementary Figure 2.1A); however, augmented panels provided higher imputation
coverage overall for lowMAF variants (Supplementary Figure 2.1B). For example, augmented panels
with 2,000 individuals from the target population (or 1,500 for Latino Americans) provided 86%,
80%, 79%, and 86% coverage for 0.1-0.25% MAF variants for Finns, Latino Americans, African
Americans, and Sardinians respectively, whereas population-specific panels alone provided 72%,
51%, 78%, and 72% coverage using the Omni Express array. However, imputation coverage for
variants with MAF>0.25% differed by <1% between augmented and population-specific panels with
2,000 individuals from the target population (or 1,500 for Latino Americans) for all populations
and genotyping arrays. When only a small number (less than 500) of individuals from the target
population are sequenced, augmented reference panels provided substantially higher imputation
coverage and r2 than population-specific panels alone. For example, augmented panels with 500
individuals from the target population provided 90%, 85%, 65%, and 85% coverage for 0.25-0.5%
MAF variants for Finns, Latino Americans, African Americans, and Sardinians respectively, whereas
population-specific panels of 500 individuals provided <30% coverage using the Omni Express array.
Even very rare variants (MAF=0.1-0.25%) attained high coverage across all populations given a
sufficient number of population-matched individuals in the reference panel. For example, attaining
>70% imputation coverage for MAF=0.1-0.25% variants required a study-specific panel of >1,800
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individuals for African Americans, 1,000 for Latino Americans, 700 for Sardinians, and 0 for Finns
using theOmniExpress. These increases in imputation coverage primarily reflect increasing numbers
of population-specific variants captured in the reference panel, which are absent from or present in
low copy number in the external panel.
We also assessed potential drawbacks of augmented reference panels relative to
population-specific panels. Using a reference panel that includes individuals outside of the
target population can result in false positive imputed variants: variants that are monomorphic in the
target population but have imputed MAC 0 and high imputation quality metrics (see also Zeggini
2011). We found that many false positive variants can be identified and filtered by comparing allele
frequencies between the sequenced and imputed samples from the target population (Supplementary
Figure 2.2).
2.3.2 Imputation Coverage and Quality across Genotyping Arrays
Imputation coveragewas generally similar for theOmniExpress andOmni2.5 arrays, but consistently
lower for the less dense Core array. Coverage differed by <7% between the OmniExpress and
Omni2.5 across all MAF bins, populations, and reference panels, whereas the Core provided up to
24% lower coverage than the Omni2.5 (Figure 2.3.1A). Imputation coverage wasmore heterogeneous
across arrays for populations with greater genetic distance from the external reference panel (e.g.,
African Americans and the HRC panel), particularly with smaller (or absent) study-specific panels
(Figure 2.3.1A). Because we used the same reference panels for each genotyping array, differences
in imputation coverage between arrays are solely due to differences in the proportion of variants
that attained imputation r2 ≥ 0.3. Imputation r2 varied more across genotyping arrays than
did imputation coverage (Figure 2.3.1B versus 2.3.1A); however, the magnitude of differences in
imputation r2 between arrays was still generally modest, particularly for the Finns and Sardinians.
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2.3.3 Powerful and Cost-Effective Strategies for GWAS across Populations
We compared the cost-effectiveness of sequencing-only, imputation-only, and
sequencing-and-imputation strategies by analyzing statistical power to detect association as a
function of numbers of study participants sequenced and imputed, genotyping array, and reference
panel across a range of genetic models. Here, we define the most cost-effective strategy as either (1)
minimizing total experimental (sequencing and genotyping) cost while attaining power at or above
a given threshold, or equivalently (2) maximizing power while maintaining cost no greater than a
specified constraint.
Figure 2.3.2: Power and Optimal Design by Population and Genotyping Array.
Power to detect association for case-control studies with equal numbers of cases and controls as a function of sequenced
subsample size (x-axis) and imputed subsample size (y-axis) for a variant with MAF 0.5% and relative risk 4 for a disease
with prevalence 1%. Axes are scaled to reflect costs of genotyping arrays (Table 2.1) and sequencing ($1K per sample).
Power shown only for designs with total genotyping cost $2M ($1.5M for Latino Americans). Dashed diagonal lines
indicate study designs with the same total cost, given by y = a− bx where a = (Total Cost)/(Array Cost) and
b = (Sequencing Cost)/(Array Cost). Circled points indicate optimal study designs, which attain the indicated
power level at minimum total experimental cost (or, maximize power at the indicated total experimental cost).
The cost-effectiveness of sequencing a subset of study participants varied greatly across
populations. For Finns, imputation-only designsweremost powerful to detect association and adding
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sequenced individuals increased power onlyminimally, even for low-frequency and rare variants. For
Sardinians, Latino Americans, and African Americans, sequencing a subset of study participants was
optimal, and often achieved substantially greater power than imputation-only or sequencing-only
studies. For example, a GWAS of African Americans with equal numbers of cases and controls in
which 800 participants are sequenced and 10,500 are imputed using the Illumina Infinium Core
array has 90% power to detect a risk variant with MAF = 0.5% and RR = 4 for a disease with
prevalence 1%, whereas an imputation-only GWAS with the same total cost (27,000 participants)
has power <70% (Figure 2.3.2). Even for populations in which optimal sequencing-and-imputation
designs had substantially greater power than imputation-only, the optimal number to sequence was
often modest. For example, only 175 participants are sequenced under the optimal design using the
Illumina OmniExpress to attain 80% power in the previous example (Figure 2.3.3). This is expected
because even a relatively small study-specific panel can substantially increase imputation coverage
(Figure 2.3.1A).
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Figure 2.3.3: Power as a Function of Minor Allele Frequency and Effect Size.
Statistical power (y-axis) to detect a rare large-effect variant (MAF=0.25%, RR=3; top row) and common modest-effect
variant (MAF=5%, RR=1.3; bottom row) for a disease with prevalence 1% as a function of the number of participants
array-genotyped and imputed (x-axis) when 0, 500, or 2,000 participants are sequenced and included in an augmented
reference panel. The number of participants sequenced has a far greater impact on statistical power for the rare variant
association. Importantly, statistical power is bounded above by the probability that the variant is imputable (r2 > 0.3
and referenceMAC ≥ 5), causing power to asymptote below 1 as a function of the number of imputed participants
(e.g., upper-left panel).
2.3.4 Denser Genotyping Arrays vs. Sequencing: Which is More
Cost-Effective to Increase Power?
Imputation coverage and power to detect association can be increased by using denser genotyping
arrays, which provide a more informative framework for imputation, or by sequencing
population-matched individuals and adding them to the reference panel. We assessed the
cost-effectiveness of these two strategies by comparing power to detect association across genotyping
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arrays for study designs that have the same total cost assuming $1000 forWGS and current list prices
for genotyping arrays (Table 2.1). As expected, the optimal number of participants sequenced to
maximize power given fixed total cost generally decreasedwith increasing array density. For example,
the optimal number sequenced to maximize power to detect association was 625, 275, and 100 for
the Infinium Core, OmniExpress, and Omni2.5 respectively for Sardinians given a risk variant with
RR = 2, MAF = 1%, and disease prevalence 1%. Power to detect association under the optimal design
given a fixed total cost was generally greater for sparser arrays; in the previous example, power under
the optimal design was 97%, 88%, and 54% for the Infinium Core, OmniExpress, Omni2.5.
We also compared optimal designs to attain power above a given threshold at minimum total cost
across genotyping arrays based on the per-sample genotyping costs reported in Table 2.1. Generally,
sparser arrays were more cost-effective (reached the power threshold with lower total cost) than
dense arrays. In fact, the sparsest genotyping array in our analysis, the Infinium Core, was most
cost-effective across all disease models and populations apart from African Americans, for whom
the Infinium OmniExpress was often most cost-effective. This last result is unsurprising given the
substantial difference in imputation coverage between the InfiniumCore andOmni arrays for African
Americans (Figure 2.3.1B). Importantly, our analysis assumes 1) a direct trade-off between the GWAS
sample size and sequencing/genotyping costs, and 2) no additional costs per GWAS sample other
than sequencing/genotyping. Under these assumptions, we found that denser arrays are generally
less cost-effective than sparser arrays; however, denser arrays provide higher imputation coverage
given a fixed GWAS sample size.
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2.3.5 Optimal Study Design as a Function of Minor Allele Frequency and
Effect Size
Power to detect association under a given study design depends on MAF, effect size (relative risk or
odds ratio), and population prevalence (Sham and Purcell 2014). These parameters also influence the
relative cost-effectiveness of sequencing and imputation. While common variants can be accurately
imputed with small reference panels, large population-matched reference panels are needed to
capture rare (population-specific) variants. In Figure 2.3.4, we illustrate the impact of sequencing on
statistical power for two combinations of MAF and effect size in each of the four study populations.
Figure 2.3.4: Optimal Design as a Function of Minor Allele Frequency and Effect Size.
Optimal numbers of participants sequenced (y-axis) and imputed (x-axis; using the Illumina OmniExpress array) to
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attain statistical power 80%.
The optimal number of study participants sequenced to attain≥80% power to detect association
at minimum total cost increases with decreasing MAF (Figure 2.3.4). This is expected, since larger
reference panels are needed to capture variants with lower frequency. In addition, the total cost
required to attain ≥80% power increases with decreasing MAF, which is expected given that power
to detect association for a given sample size decreases with decreasing MAF. The optimal number
to sequence to attain≥80% power decreases with increasing effect size magnitude. This is expected,
since the expected number of risk alleles captured in the reference panel increases with effect size
magnitude.
2.4 Discussion
While the cost of genome sequencing has fallen dramatically ((KA, 2018)), large genome sequencing
studies remain prohibitively expensive. Large reference panels are now enabling accurate imputation
of even very rare variants (S. McCarthy et al. 2016; Zhou et al. 2017; Mahajan et al. 2018),
making imputation-based GWAS viable and cost-effective for detecting associations across the
allele frequency spectrum. For populations with limited reference panel data, we have shown
that sequencing a subset of study participants can substantially increase imputation coverage and
accuracy, particularly for rare and population-specific variants, at a fraction of the cost of sequencing
the entire study cohort. Our results also suggest that it is almost always advantageous to augment
existing reference panels, except when the study-specific panel is large or the target population has
high genetic distance from the external panel.
Complementary sequencing-and-imputation GWAS strategies have been applied to refine
association signals and discover novel associations for several populations and complex traits (Pistis
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et al. 2015; Auer and Lettre 2015; Holm et al. 2011). While most sequencing-and-imputation studies
to date have been carried out in European isolated populations, our results suggest that this strategy
can also be powerful and cost-effective for admixed and non-European populations. In addition to
increasing genomic coverage and power to detect association for the study itself, sequencing a subset
of study participants provides a data resource that can be used to enhance imputation in future studies
of the same or related populations.
Directly augmenting an existing reference panel with study-specific sequence data is not always
feasible due to technical, logistical, and privacy constraints. However, we and others have found that
the distributed reference panel approach (separately imputing with two ormore reference panels and
combining the results) provides nearly equivalent imputation quality (Supplementary Figure 2.3).
Thus, study-specific WGS data can be used to improve imputation even when directly augmenting
an external panel is not feasible.
While large reference panels enable accurate imputation across a wide range of the allele
frequency spectrum (S.McCarthy et al. 2016; Zhou et al. 2017), the extent of genetic variation that can
be captured through imputation is limited relative toWGS. For example, de novomutations cannot be
imputed regardless of reference panel size. This is particularly salient for monogenic disorders; for
example, over 80% of achondroplasia cases occur from recurrent de novomutations in FGFR3(Bellus
et al. 1995). Thus, imputation may be unable to detect causative alleles for traits with extreme genetic
architectures, even with very large reference panels.
As increasingly large and diverse sequencing projects are conducted, larger and more diverse
reference panels will become available. In the design and planning of GWAS, it may be prudent to
consider resources under development and pending release in addition to resources that are currently
available. More broadly, our analysis highlights the utility of collaboration and coordination across
institutions for effective study design and resource allocation. For example, the optimal design to
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maximize power in an individual study does not necessarily maximize meta-analysis power across
multiple studies of the same trait and population.
Our analysis of cost-effectiveness and optimal design depends crucially on the relative per-sample
costs of sequencing and array genotyping. Both sequencing and genotyping costs have fallen
markedly in recent years, and are likely to continue to do so. Depending on the relative rates of
change, cost-effectiveness and optimal design also may change. In addition, the cost of participant
recruitment and DNA sample collection may alter the relative cost-effectiveness of sequencing and
genotyping. Finally, our cost-effectiveness analysis assumes that sample size is unconstrained, and
may not apply for small populations or rare diseases. While our results are illustrative, investigators
may wish to explore questions of the relative cost-effectiveness of sequencing and array genotyping
strategies in the context of their own study and relevant assumptions about population, reference
panels, and sequencing and array genotyping costs. To enable this exploration, we have developed a
flexible, easy-to-use software tool, APSIS (Analysis of Power for Sequencing and Imputation Studies),
to analyze power and identify optimal study designs while accounting for imperfect imputation
coverage and accuracy.
2.4.1 Conclusions
Here, we assessed the genomic coverage, statistical power, and cost-effectiveness of sequencing
and imputation-based designs for GWAS in a variety of populations and a range of genetic
models. We developed a novel method to account for available reference haplotype data in power
calculations using empirical data, which can be applied to inform GWAS planning and design. For
European populations that are well-represented in current reference panels, our results suggest that
imputation-basedGWAS is cost-effective andwell-powered to detect both common- and rare-variant
associations. For populations with limited representation in current reference panels, we found that
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sequencing a subset of study participants can substantially increase genomic coverage and power to
detect association, particularly for rare and population-specific variants. Our results also suggest that
larger and more diverse reference panels will be important to facilitate GWAS in global populations.
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2.6 Appendix: Supplementary Figures
Supplementary Figure 2.1: Imputation Coverage and r2 as Functions of Population-Specific
Reference Panel Size.
(A) Imputation coverage, defined as the proportion of variants with imputation r2 ≥ 0.3 and minor
allele count (MAC)≥ 5 in the reference panel, and (B) imputation r2, defined as the squared Pearson
correlation between true genotype and imputed dosage, as a function of study-specific reference
panel size (Number Sequenced).
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Supplementary Figure 2.2: Filtering False-Positive Imputed Variants.
ROC and Precision-Recall curves for detecting false-positive imputed variants (variants with true
MAC = 0, butMACimputed ≥ 5 and imputation r2 ≥ 0.3) using the two-sample t-test statistic of
allele frequencies between the imputed and sequenced subsamples. Results are shown for African
Americans variants based on a sequenced subsample size of 1,400 and imputed subsample size of
1,412. Out of 656K variants with imputed MAF≥ 0.1% and imputation r2 ≥ 0.3, 11K variants
(1.7%) have true MAC=0. Area under the ROC curve = 0.94, and area under Precision-Recall curve
= 0.34.
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Supplementary Figure 2.3: Imputation r2 for Augmented versus Distributed Reference Panels.
Imputation r2 for augmented reference panels (directly augmenting the HRC or HRC subset with
study-specific sequence data) versus a distributed reference panel approach, in which participants
are separately imputed with the HRC (or HRC subset) and the study-specific reference panel
merged by selecting the MaCH- rˆ2. Results are shown for the Omni Express array, and study
specific reference panel sizes of 2,000 for African Americans, Finns, and Sardinians and 1,500 for
Latino Americans. he mean pairwise difference in imputation r2 across variants between
augmented and distributed panels was < 0.005 in magnitude for each population.
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Supplementary Figure 2.4: Optimal Designs for a Common Variant with Moderate Effect.
Power to detect association for case-control studies with equal numbers of cases and controls as a
function of sequenced subsample size (x-axis) and imputed subsample size (y-axis) for a variant
with MAF=10% and relative risk 1.5 for a disease with prevalence 1%. Axes scaled to reflect costs of
genotyping arrays (Table 2.1) and sequencing ($1K per sample). Power shown only for designs with
total genotyping cost≤ $2M ($1.5M for Latino Americans). Dashed diagonal lines indicate study
designs with the same total cost, given by y = a− bx where a = (Total Cost)/(Array Cost) and
b = (Sequencing Cost)/(Array Cost). Circled points indicate optimal study designs, which
attain the indicated power level at minimum total experimental cost (or, maximize power at the
indicated total experimental cost). In this example, exclusively array-based genotyping and
imputing from the external HRC panel is optimal for all populations considered.
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Supplementary Figure 2.5: Optimal Designs for a Rare Variant with Large Effect.
Power to detect association for case-control studies with equal numbers of cases and controls as a
function of sequenced subsample size (x-axis) and imputed subsample size (y-axis) for a variant
with MAF=0.3% and relative risk 6 for a disease with prevalence 1%. Axes scaled to reflect costs of
genotyping arrays (Table 2.1) and sequencing ($1K per sample). Power shown only for designs with
total genotyping cost≤ $2M ($1.5M for Latino Americans). Dashed diagonal lines indicate study
designs with the same total cost, given by y = a− bx where a = (Total Cost)/(Array Cost) and
b = (Sequencing Cost)/(Array Cost). Circled points indicate optimal study designs, which
attain the indicated power level at minimum total experimental cost (or, maximize power at the
indicated total experimental cost). In this example, sequencing a subset of participants is almost
uniformly optimal across populations, with the exception of Finns.
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Chapter 3
emeraLD: Rapid Linkage Disequilibrium Estimation with
Massive Data Sets
1
3.1 Introduction
Linkage disequilibrium (LD) – pairwise association between alleles at different genetic variants – is of
fundamental interest in population genetics as a vestige of natural selection and demographic history,
and is essential for a wide range of analyses from summary statistics in genome-wide association
studies (GWAS). Motivated by restrictive data sharing policies and logistical constraints, a variety of
methods have been developed for analysis of GWAS summary statistics (single-variant association
statistics) rather than individual-level data. For example, summary statistics-based methods have
been developed for fine-mapping (Benner, Spencer, et al. 2016), conditional association (Yang et al.
2012), gene-based association (Bakshi et al. 2016; Barbeira et al. 2016; Lamparter et al. 2016),
heritability estimation (Bakshi et al. 2016), and functional enrichment analysis (Finucane et al. 2015;
1This work has been published (Quick et al. 2018)
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Lamparter et al. 2016). These methods generally rely on LD estimates from an external data set,
which are ideally calculated on-the-fly rather than precomputed and stored due to prohibitive storage
costs. For example, the 1000 Genomes Project Phase 3 panel includes over 35M shared variants
(1KGP Consortium 2015), which corresponds to over 4 × 1011 pairwise LD coefficients within 1
Mbp windows genome-wide.
3.1.1 Existing Tools to Estimate LD
Existing tools to estimate LD generally scale linearly with sample size, prompting a need for more
efficient methods for large data sets. PLINK is a widely used software toolkit for analyzing genetic
data, and is among the most computationally efficient tools for estimating LD (Shaun Purcell et al.
2007; Purcell and Chang 2016). PLINK’s BED genotype data format allows efficient querying and
data processing, but demands prohibitive storage space for large sample sizes and large numbers
of markers (e.g., 7.6TB for the TOPMed Whole Genome Sequencing Project, which includes >60K
individuals). VCFtools is anotherwidely used software toolkit formanipulating and analyzing genetic
data in the Variant Call Format (VCF) (Danecek et al. 2011). Compressed VCF files (VCF.gz) require
far less storage space than BED files (e.g., >30× less storage space for the TOPMedWGS Project), and
permit random access of genomic regions through block-compression and Tabix indexing (Danecek
et al. 2011; Li 2011). VCFtools provides utilities to estimate LD fromVCF files, but is computationally
burdensome for large data sets. M3VCF format uses a compact haplotype representation that requires
far less storage than genotype formats (Das et al. 2016). m3vcftools provides efficient utilities for
estimating LD with M3VCF format, but is substantially slower than PLINK with BED file input.
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3.2 Methods
3.2.1 LD Statistics
Three common measures of LD are the LD coefficient D (the covariance of genotypes), the
standardized LD coefficient D′ (D divided by its maximum value given allele frequencies), and the
Pearson correlation r or its square (Gabriel et al. 2002). Each of these statistics can be written as a
function of allele frequency estimates, sample size, and dot product of genotype vectors. Importantly,
only the dot product must be calculated for each pair of variants to calculate LD, since allele
frequencies and haplotype counts can be precomputed when processing genotype data.
3.2.2 Computational Approach
We tailored our computational approach to exploit the structure of each supported input data
format. For genotype formats (e.g., VCF Danecek et al. 2011), we calculate the dot product using
sparse-by-dense and sparse-by-sparse vector products. Using haplotype block format (M3VCF Das
et al. 2016), we can calculate the dot product using within-block and between-block haplotype
intersections.
Sparse Representation of Phased Genotypes For each variant, we keep a {0, 1}2n vector of
genotypes (where 1 indicates the minor allele) and sparse vector containing the indexes of non-zero
entries. If the major allele is non-reference in the input file (allele count greater than n), we reverse
the sign of its LD coefficients for consistency. Letting Cj = {i|Gij = 1} denote the set indexing
minor-allele carriers of variant j, the dot productmjk := Gj ·Gk between variants j and k can be
calculated in min(mj,mk) operations, where mj is the minor allele count (MAC) for variant j, by
using the sparse-by-dense product formulamjk =
∑
i∈Cj Gik.
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Sparse Representation of Unphased Genotypes For unphased genotypes, we store a {0, 1, 2}n
vector of genotypes and sparse vectors indexing heterozygotes and minor-allele homozygotes for
each variant. In this case, LD between two variants can be calculated in min(Nj1 +Nj2, Nk1 +Nk2)
operations, whereNji is the number of individuals with genotype i at variant j.
Haplotype Block Representation A haplotype is a sequence of contiguous alleles along a
chromosome within a genomic region, or haplotype block. Due to the limited diversity of human
haplotypes (Wall and Pritchard 2003), the number of distinct haplotypes in a block with J biallelic
variants is typically small relative to the sample sizen or number of possible haplotypes 2J (whichever
is smaller). M3VCF formatmaps each sample to a haplotypewithin each block, andmaps each variant
in a block to the set of haplotypes that contain the non-reference allele (Das et al. 2016). GivenM3VCF
input, we precompute the number of observationsN bh of each haplotype h for each block b, and index
the set of haplotypes Hbj containing the minor allele at each variant j in block b. For two variants j
and k in the same block, the dot product can then be calculated in at most min(cbj, cbk) operations,
where cbk = #Hbk is the number of distinct haplotypes that carry the minor allele at variant k, using
the sparse-by-dense product formula mjk =
∑
h∈Hbj 1Hbk(h)N
b
h. To calculate LD for variants in
different blocks, we can compute a between-block count matrix Nabhh′ , the number of samples with
haplotype h in block a and haplotype h′ in block b. The dot product between variants j and k can
then be calculated in caj × cbk operations using the formulamjk =
∑
h∈Haj
∑
h′∈Hbk N
ab
hh′ . In practice,
sparse-by-dense genotype products are typically more efficient for between-block calculations.
Informed Subsampling to Estimate LD with Large Sample Sizes When both variants j and
k have large MAC (e.g., common variants and/or large sample sizes), calculating sparse-by-dense
products to estimate LD becomes expensive. In this case, we use an informed subsampling approach
to efficiently estimate LDwhile maintaining a user-specified bound on the precision of LD estimates.
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We treat the sample correlation r = (pjk−pjpk)/sjsk as a parameter to be estimated by informed
subsampling. Here, pj, pk, sj and sk can be calculated efficiently and stored; because pjk must be
calculated for each pair of variants, we subsample from the carriers of the rarest allele to increase
computational efficiency. In Supplementary Materials, we show that the approximate estimator r˜`
can be calculated in at most ` operations for any pair of variants, and increases the mean squared
error (MSE) by no more than 1/` relative to exact LD estimates (or 2/` for unphased genotypes),
where ` is a user-specified parameter. In very large data sets (n > 50K), subsampling with ` = 250
decreased computation time for common variants (MAF > 5%) by an order of magnitude or more.
3.3 Results
3.3.1 Implementation and Usage
We implemented our algorithms as an open-source C++ tool, emeraLD (efficient methods for
estimation and random access of LD), which can be used via command line or through an R interface
included with source files. emeraLD accepts block compressed VCF.gz and M3VCF.gz input, and
leverages Tabix (Li 2011) and the C library HTSlib to support rapid querying and random access of
genotype data over genomic regions. emeraLD implements several options to customize output fields
(variant information and LD statistics) and formats (long tables or square symmetric matrices). We
also provide tools to facilitate estimating LD from a reference panel for analysis of GWAS summary
statistics.
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3.3.2 Performance
Table 3.1: Benchmarking: CPU Time and Memory Usage
Tool: m3vcftools PLINK 1.9 LDstore emeraLD* Absolute*
Format: M3VCF.gz BED BGEN M3VCF.gz
CPU Time Relative to emeraLD
1KGP 18.8 1.3 4.4 1.0 8.5 m
HRC 44.7 6.8 16.8 1.0 2.6 m
UKB 473.7 128.4 250.6 1.0 19.9 m
Memory Usage Relative to emeraLD
1KGP 0.7 137.6 372.4 1.0 43.8 MiB
HRC 0.6 10.7 26.1 1.0 156.9 MiB
UKB 0.4 4.7 4.8 1.0 4.8 GiB
Time and memory to calculate LD in a 1Mbp region of chr20 (28,126 variants in 1KGP; 13,174 in HRC; and 32,783 in
UKB). All experiments were run on a 2.8GHz Intel Xeon CPU. emeraLD
*Absolute time or memory for emeraLD as reference
We used WGS genotype data from the 1000 Genomes Project Phase 3 (1KGP; n = 2,504) (1KGP
Consortium 2015), Haplotype Reference Consortium (HRC; n = 32,470) (McCarthy et al. 2016),
and imputed genotype data from the UK Biobank (UKBB; n = 487,409) to compare performance
between emeraLD and PLINK v1.9 (Purcell and Chang 2016), LDstore (Benner, Havulinna, et al.
2017), VCFtools (Danecek et al. 2011), and m3vcftools (Das et al. 2016). For UKB, emeraLD from
M3VCF.gz file input is >100× faster than PLINK from BED files (Table 3.1), which are >10× larger
than VCF.gz and >30× larger than M3VCF.gz. For HRC, which includes 32K individuals and only
variants with MAC ≥5, emeraLD calculates LD from M3VCF.gz files >6× faster than PLINK from
BED files, which are >4× larger than VCF.gz and >20× larger than M3VCF.gz. Times reported for
emeraLD used ` = 1, 000 (MSE of approximation ≤ 0.001); this has a negligible effect for 1KGP,
but reduced overall computation time by ~50% for UKB and HRC. Using M3VCF.gz files reduced
computation time for emeraLD by ~30-50% relative to VCF.gz.
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3.3.3 Applications
Our approach will be implemented in a forthcoming web-based service capable of providing LD
information from large panels with >60K samples, such as the TOPMed WGS project, in real
time. This enables use of improved LD information by rapidly emerging and gaining in popularity
web-based interactive analysis and visualization tools such as LocusZoom (Pruim et al. 2010).
We have also used emeraLD to estimate LD for gene-based association and functional enrichment
analysis of GWAS summary statistics. This approach avoids precomputing and storing LD without
compromising speed – for example, we developed an implementation of the MetaXcan gene-based
association method (Barbeira et al. 2016) using emeraLD to estimate LD on-the-fly, which is
~5× faster than the original implementation using precomputed LD estimates. To enable simple
integration with R scripts or libraries, we include an R interface to emeraLD with source files.
3.4 Conclusions
Here we described computational and statistical methods to efficiently estimate LD with large
data sets. Our methods exploit two natural features of genetic data: sparsity that arises from the
abundance of rare variation, and high redundancy that arises from haplotype structure. We also
developed an informed subsampling approach to further improve computational efficiency while
maintaining a user-specified bound on precision relative to exact LD estimates. Finally, we described
an open-source software implementation that can be used to facilitate analysis of GWAS summary
statistics.
45
3.5 Acknowledgments
I thank RyanWelch, Daniel Taliun, Sayanatan Das, and Christian Fuchsberger for helpful suggestions
and assistance with the algorithms and software implementation. I also thank the cohorts and staffs
of the Haplotype Reference Consortium, 1000 Genomes Project Consortium, and the UK Biobank
Resource. This research has been conducted using the UK Biobank Resource under Application
Number 24460.
46
3.6 Appendix: Supplementary Methods & Figures
Here we describe subsampling techniques to approximate linkage disequilibrium (LD) between
biallelic variants. We begin with the case where haplotype phase is known (genotypes take values
0 or 1), followed by the case where phase is unknown (genotypes take values 0, 1, or 2).
We treat the sample correlation r = (pjk − pjpk)/sjsk as a parameter to be estimated by
subsampling. Here, minor allele frequencies pj and pk (and standard deviations sj and sk) can
be calculated efficiently and stored; because pjk must be calculated for each pair of variants, we
approximate to increase computational efficiency. For convenience, we treat allele frequencies as
known constants.
Informed Subsampling with Phased Genotypes
Here, we describe a subsampling approach to approximate the sample correlation r = (pjk −
pjpk)/sjsk using phased genotypes. Consider the estimator r˜(`,∆) = [p˜jk(`,∆) − pjpk]/sjsk ,
where
p˜jk(`,∆) =

pj
`
∑`
i=1 G˜
(j)
ik ∆ = 1
pk
`
∑`
i=1 G˜
(k)
ij ∆ = 0
for∆ ∈ {0, 1} and where each G˜(j)ik (or G˜(k)ij ) is independently sampled from the subset of haplotypes
withGij = 1 (orGik = 1).
Clearly r˜(`,∆) is an unbiased estimator for r, and has empirical variance
varn[r˜(`,∆)] =
pjk
`s2js
2
k
[
∆p2j(pj − pjk) + (1−∆)p2k(pk − pjk)
]
.
Therefore, given that we sample `minor allele carriers of either variant j or variant k, the optimal
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estimator r˜` is given by taking ∆ = I(pj ≤ pk). Intuitively, carriers of the rarer allele are more
informative for estimating the size of the intersection.
Letting ρ denote the true LD value in the population, the MSE of the approximate estimator is
MSE(r˜`) := E[(r˜` − ρ)2] = E[(r − ρ)2] + E[(r˜` − r)2],
so for pj ≤ pk (WLOG) we have MSE(r˜`)−MSE(r)= (pj − pjk)pjk/`s2js2k.
The variance of the estimator is maximized with respect to pjk when pjk = pj/2, and maximized
with respect to pj when pj = 1/2 (because 1/2 ≥ sk ≥ sj ≥ pj ). It follows that MSE(r˜`) −
MSE(r) ≤ 1/`.
Informed Subsampling with Unphased Genotypes
Here, we describe a subsampling approach to approximate the sample correlation r = cjk/sjsk
using unphased genotypes. We define the sample covariance between variants j and k as cjk =
1
n
∑n
i=1GijGik − 4pjpk, and we can write
1
n
n∑
i=1
GijGik = pk,1Eˆ(Gj|Gk = 1) + 2pk,2Eˆ(Gj|Gk = 2)
where pk,m is the proportion of individuals with genotypem at variant k, and Eˆ(Gj|Gk = m) is the
mean genotype at variant j among individuals with genotypem at variant k in the overall sample of
n individuals.
Define the approximate estimator
c˜jk(`1, `2) = pk,1E˜`1(Gj|Gk = 1) + 2pk,2E˜`2(Gj|Gk = 2)− 4pjpk,
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where E˜`(Gj|Gk = m) is estimated by sampling ` genotypes from individuals with genotypem at
variant k. The approximate estimator is unbiased and has empirical variance
varn[c˜jk(`1, `2)] =
p2k,1
`1
varn(Gj|Gk = 1) +
4p2k,2
`2
varn(Gj|Gk = 2).
Supposing that variants j and k are independent (which maximizes the variability of the
estimator),
varn[c˜jk(`1, `2)] =
(
p2k,1
`1
+
4p2k,2
`2
)
s2j ,
which is minimized by choosing `1 : `2 in proportion to pk,1 : 2pk,2, or in other words oversampling
homozygotes by a factor of 2.
We can now define the optimal approximate estimator c˜`jk = c˜jk(`∗1, `∗2), where
`∗1 =
pk,1
2pk,2 + pk,1
` and `∗2 =
2pk,2
2pk,2 + pk,1
`.
Therefore, the optimal approximate estimator has varn(c˜`jk) ≤ 4p2ks2j/` (note that 2pk = pk,1 +
2pk,2), and letting r˜` = c˜`jk/sjsk , we have
MSE(r˜`)−MSE(r) = varn(r˜`) ≤ 4p
2
k
`s2k
≤ 2
`
.
Here, we have not assumed Hardy-Weinberg Equilibrium (HWE) for either variant. Supposing
that both variants are inHWE,we canwrite Eˆ(GjGk) = 2pjk(1+pj+pk−pjk)+2(pk−pjk)(pj−pjk),
and because pjk is the only unknown parameter, the most efficient subsampling estimator would use
as many minor-allele homozygotes as possible before sampling any heterozygotes. We avoid this
assumption to ensure that estimates are robust.
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Time Complexity of Approximation by Informed Subsampling
By subsampling ` individuals or haplotypes whenever min(MACj,MACk) > `, we are guaranteed
at most ` operations for each pair of variants. For computational efficiency, we sample subsets of
minor-allele carriers once for each variant as genotype data are processed.
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Supplementary Figure 3.1: Approximate vs. Exact LD Estimates.
Here, we show approximate vs. exact LD estimates from the Haplotype Reference Consortium. The
number of minor-allele carriers sampled ` is equal to 1/∆MSE , where ∆MSE is the maximumMSE
induced by approximation.
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Chapter 4
Leveraging Functional Genomic Annotations to Identify
Causative Genes and Biological Mechanisms Underlying GWAS
Associations
4.1 Introduction
Genome-wide association studies (GWAS) have identified thousands of genetic loci associated with
hundreds of complex traits (Welter et al. 2013). However, the biological mechanisms underlying
these associations are often poorly understood. The majority of GWAS associations to date are
in non-coding regions of the genome, making it difficult to identify causal genes, let alone dissect
genetic etiology in more detail. The Roadmap Epigenomics project (Bernstein et al. 2010), ENCODE
(ENCODE Project Consortium 2012), GTEx (GTEx Consortium 2015), FANTOM5 (Lizio et al.
2015), and other consortia have fueled significant advances in regulatory genomics, and have
provided valuable public data resources for studying the activity of regulatory elements and potential
functional effects of non-coding variation. Integrating these large and complex data to better
understand GWAS associations is a highly active area of research, and has presented enticing new
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possibilities for GWAS researchers as well as formidable computational and statistical challenges.
Identifying Causal Variants Narrowing down the most likely causal variants underlying GWAS
association signals is an important step toward identifying causal mechanisms. While linkage
disequilibrium (LD) has been invaluable for identifying causal loci– first exploited in gene mapping
studies, and later in genotype imputation algorithms– it complicates the identification of causal
variants, forming dense clusters of highly correlated association statistics. To address this challenge, a
Bayesian framework is often used to finemap associated loci, which involves calculating Bayes factors
to identify sets or configurations of variants with the highest posterior probability of being causal
(Y. Lee et al. 2018; Wen et al. 2016; Benner et al. 2016). Variants identified through finemapping can
be cross-referenced with functional annotations to assess potential causal mechanisms (e.g., J. Z. Liu
et al. 2012; Farh et al. 2015; Huang et al. 2017); however, this approachmay ormay not be informative
for identifying causal genes.
Identifying Causal Genes Gene-based association tests provide a more interpretable framework
for association analysis, and can increase power to detect association by aggregating effects across
variants and reducing the burden of multiple testing (D. J. Liu et al. 2014; Sham and Purcell 2014).
Often, variants are grouped based on their putative functional effects, e.g., rare non-synonymous
variants for a given gene (D. J. Liu et al. 2014; Morrison et al. 2013). Amore recent class of gene-based
association tests have been developed for eQTL variants, e.g. PrediXcan (Gamazon et al. 2015;
Barbeira et al. 2016) and TWAS (Gusev et al. 2016), which were proposed as tests of association
between the genetic component of gene expression and traits. These expression-based tests employ
the logic of Mendelian randomization to estimate causal effects: since genotype precedes phenotype,
the direction of causality between phenotype and the genetic component of expression– a function of
genotype– is unambiguous (Gusev et al. 2016; Hauberg et al. 2017). More broadly, many gene-based
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association tests can be viewed as proxy variable methods in which intermediate phenotypes, e.g.
protein dysfunction or tissue-specific expression, are hypothesized to mediate association. However,
as in the analysis of single variants, LD is a potential source of confounding for gene-based association,
which complicates the mechanistic interpretation of these statistics.
Purpose Here, we develop a statistical framework and computational tool to integrate regulatory
and functional genomic datasets with GWAS summary statistics to identify causal genes and
biological mechanisms underlying associations. We describe a novel gene-centered Bayesian model
that accounts for multiple potential mechanisms underlying GWAS association signals, and use
an approximate E-M algorithm to efficiently estimate hyperparameters. A central premise of this
approach is to utilize functional enrichment to update prior weights for groups of variants; this
approach has been used to improve the accuracy of single-variant finemapping (Y. Lee et al. 2018;
Wen et al. 2016), but has not been applied in gene-based analysis. We compiled an integrative
annotation dataset that maps functional variants to likely target genes by aggregating data sets from
Roadmap/ENCODE (Cao et al. 2017; Bernstein et al. 2010; ENCODE Project Consortium 2012),
FANTOM5 (Marbach et al. 2016; Cao et al. 2017; Lizio et al. 2015), and GTEx (GTEx Consortium
2015; Gamazon et al. 2015; Barbeira et al. 2016). We present a software toolkit and implementation of
our methods, which leverages functional annotations to simultaneously examine a range of potential
genes, mechanisms, and pathways underlying association signals. Finally, we discuss an application
to 25 diverse traits using GWAS summary statistics from the UK Biobank.
4.2 Methods
We describe 1) a statistical model that explicitly maps functional variants to genes to identify
genes implicated by association signals, 2) methods to aggregate variants for gene-based analysis,
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3) algorithms to estimate the model and inference procedures using GWAS association summary
statistics and LD estimates, 4) functional genomic data resources we used to annotate functional
variants, 5) procedures to simulate GWAS data using real genotype and functional annotation data,
and 6) GWAS data from the UK Biobank to which we applied our methods.
4.2.1 Model Definitions and Assumptions
Mediation as a Conceptual Basis for Genetic Association
The molecular mechanisms underlying complex traits are intricate, and involve many complex
processes interacting over time at the cellular level and beyond. Here, we describe a simple model
for complex traits as a conceptual basis, which is motivated by the intuition that cellular phenotypes
(e.g., gene expression levels, protein functionality) mediate the causal associations between genetic
variants and traits.
For a phenotype Yi with mean 0 and unit variance, we consider a linear model
Yi =
∑
g
α>gMig + i
whereMig is a vector of cellular phenotypes for gene g and i is an environmental component. In
turn, we modelMi = (M>i1 ,M>i2 , ...)> as a linear function of genotypes,
Mi = ΛGi + ei
where each element of the genotype vector Gi has mean 0 and unit variance. In practice, the
functional effects of genetic variants (denoted by Λ) are typically unknown, and cellular phenotypes
Mi are typically unobserved in GWAS (unless additional omics data have been collected). We
use functional genomic data to construct a proxy matrix Λ˜ specifying effects of genetic variants
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on gene-based cellular phenotypes. We then aggregate groups of variants based on functional
annotations to construct proxy cellular phenotypes, which serve as the unit of association in our
approach.
Using external functional genomic data to construct proxies for cellular phenotypes has been
widely applied in methods such as TWAS and PrediXcan (Gusev et al. 2016; Gamazon et al. 2015),
which can be conceptualized as tests of association between the predicted genetic component of
tissue-specific gene expression levels andGWAS trait. However, thesemethods can be confounded by
LD and pleiotropy (illustrated in Figure 4.2.1), rendering a causal interpretation ambiguous. Here,
we aggregate diverse and comprehensive functional genomic annotation databases to account for
multiple possible mechanisms underlying association. This approach lessens the potential for LD or
pleiotropy-induced confounding, although such confounding is still possible due to incomplete and
imprecise annotations. In addition, we assume that genetic associations reflect causal genetic effects,
and ourmethods will be affected by confounding caused by un-adjusted technical factors, population
structure, or relatedness in GWAS data.
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Figure 4.2.1: Causal Diagrams: Mediation as a Conceptual Basis for Genetic Association
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Path diagrams for four scenarios. In each subpanel,G = (G1, G2, G3, G4)> represents genotypes at four genetic
variants, which are potentially correlated due to LD (gray undirected edges).M = (M1,M2)> represent intermediate
cellular phenotypes (e.g., cell-type-specific mRNA expression levels for a given transcript, protein functionality, protein
stability, etc.). The trait of interest is indicated in the upper right corner of each subpanel, and U in the lower right
represents an unmeasured confounding variable. Here, we do not useM directly (and in general do not measureM
directly); instead, we use genotypes to construct proxies M˜ to assess association with the trait of interest. Importantly,
since M˜ is constructed solely from genotype, it can be used for valid causal inference even whenM is confounded.
In Panel A, the intermediate phenotypeM2 and the trait of interest are both downstream of counfounding variable U .
However, because genotypesG are independent of U , we can construct a valid instrumental variable fromG to
estimate the causal effect ofM2 on trait (dashed line) if it exists.
In Panel B,G affects the trait throughM2. However, becauseM1 is downstream of the trait,G also indirectly affects
M1. Thus, a proxy variable M˜1 constructed fromGmay lead to the erroneous conclusion thatM1 affects the trait.
Panel C depicts LD-induced confounding. Here, onlyM1 has a causal affect on the trait. However, we may detect a
statistical association between M˜2 and trait due to LD betweenG3 (which affectsM2) withG1 andG2 (which affect
M1).
Panel D depicts pleiotropy. Here, onlyM1 has a causal affect on the trait. However, we may detect a statistical
association between M˜2 and trait becauseG2 affects bothM1 andM2.
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4.2.2 Aggregating Variants for Gene-Based Analysis
Gene-based Test Statistics
Table 4.1: Gene-Based Association Tests
Gene-based Test Test Statistic Comments Synonyms & Special Cases
Q-form (Quadratic) Z>WZ W = diagonal weight matrix SKAT, SOCS
L-form (Linear) w>Z w = weight vector Burden test, TWAS & PrediXcan
M-form (Min/Max) maxj |Zj|2 Alternatively, minj p-valuej MOCS
Here, we review common gene-based association tests and their interpretation in the proposed
framework. The oldest and most widely used gene-based tests are linear combinations of z-scores
(B. Li and Leal 2008; S. Lee, Wu, and Lin 2012), here referred to as L-form tests (Table 4.1). Examples
of L-form tests include the burden test (B. Li and Leal 2008), which aggregates rare, putatively
deleterious mutations; and TWAS/PrediXcan tests (Gamazon et al. 2015; Gusev et al. 2016), which
aggregate eQTL variants using prediction weights estimated from external eQTL mapping data, e.g.
GTEx. These can be viewed as tests of association between GWAS trait and an explicit proxy variable
constructed as a linear combination of genotypes. Importantly, L-form tests rely on prior knowledge
regarding the directions of effect across variants. For example, burden tests are appropriate when
rare deleterious alleles are hypothesized to increase risk for disease, and TWAS/PrediXcan tests
(using predictive weights) are appropriate when gene expression levels are hypothesized to affect
trait. Another common form of gene-based test is the sum of squared z-scores across variants, here
referred to as Q-form tests. While less tractable than L-form, analytical p-values for Q-form tests
can be calculated using a variety of techniques to approximate the tail probabilities of multivariate
normal quadratic forms (e.g., Davies 1980; H. Liu, Tang, and H. H. Zhang 2009). Q-form tests are
most appropriate when a sizable proportion of variants are hypothesized to have non-zero effects
of unknown and inconsistent direction (S. Lee, Wu, and Lin 2012). Finally, perhaps the simplest
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gene-based test is the maximum absolute z-score across variants (or equivalently, the minimum
p-value), here referred to as M-form tests. Analytical p-values for M-form tests can be calculated
by directly integrating the multivariate normal density of z-scores within the hypercube given by
x ∈ Rm : maxk |xk| ≤ maxj |Zj| wherem is the number of variants, or approximated by adjusting
the minimum p-value across variants by the effective number of tests (Conneely and Boehnke 2007).
M-form tests are most appropriate when only a small proportion of variants are hypothesized to
have non-zero effects. Unlike L-form tests, Q-form and M-form do not involve constructing an
explicit proxy variable; however, they can be viewed as testing association between GWAS trait and
a proxy variable constructed with stochastic weights. For example, a M-form test across variants
within a regulatory element could be used to assess evidence that regulatory perturbations of a given
gene affects GWAS trait, supposing that only a single unknown variant within the regulatory element
perturbs gene regulation.
It is interesting to note the mathematical relationships among these three forms and the variety
generalizations and possible extensions. Q-form andM-form can both be viewed as special cases of a
more general statistic Sp = (
∑
j |Zj|p)1/p, which is equivalent to Q-form (withW = I) when p = 2,
and equivalent to M-form when p→∞; the Sp generalized form has been used, for example, in the
aSPU gene-based test (Kwak and Pan 2015). Similarly, Q-form and L-form can both be viewed as
special cases of a more general statistic Spi = Z>(piW + (1 − pi)ww>)Z , which is equivalent to
Q-form when pi = 1 and L-form when pi = 0; the Spi generalized form has been used, for example,
in the SKAT-O gene-based test (S. Lee, Wu, and Lin 2012). Here, we focus primarily on using prior
biological knowledge to inform gene-based analysis, and use only the basic gene-based test forms
given in Table 4.1.
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Gene-based Bayes Factors
In this section, we outline a Bayesian perspective of gene-based association analysis and provide
Bayes factors corresponding to various prior distributions for the genetics effects on GWAS trait.
Here and elsewhere, genetic effect sizes β are scaled such that β2j is equal to the proportion of trait
variance accounted for by the effect of variant j. We consider three distributional forms for the prior
distribution of genetic effect sizes β:
1. Linear prior in which weights w are used to construct an explicit proxy phenotype M˜i =
w>Gi. We assume that the effect size of the intermediate phenotype on trait is α ∼ N (0, τ),
which implies β is multivariate normal with mean 0 and the degenerate covariance matrix
ww>τ . We use this approach to aggregate eQTL variants using precomputed prediction
weightsw scaled such thatw>Rw = 1.
2. Dispersed prior in which all variants have non-zero effect sizes, but magnitude and direction
are unknown. Specifically, we assume β ∼ Nm(0, Im τm) wherem is the number of variants.
We use this approach to aggregate groups of coding variants and variants in regulatory
elements.
3. Sparse prior in which only a single variant has a non-zero effect. Specifically, the causal
variant j∗ is uniformly distributed over {1, 2, ..., m} where m is the number of variants, and
βj∗ ∼ N (0, τ). We use this approach to aggregate groups of coding variants and variants in
regulatory elements.
We define the Bayes factor BFs for a prior model A as
BF =
fβˆ|A(βˆ)
fβˆ|β≡0(βˆ)
, (4.2.1)
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where βˆ denotes the MLE of effect sizes. In general, we do not explicitly calculate βˆ; rather, we
reconstruct the Bayes factor using single-variant z-scores Z and LD matrix R. This approach has
been widely applied previously for single-variant Bayesian finemapping (e.g., Y. Lee et al. 2018). The
sampling distribution of the MLE βˆ is approximately
n1/2(βˆ − β) a∼Nm(0, σ2Y R−1) (4.2.2)
where σ2Y is the trait variance, and R is the LD matrix. Equation 4.2.2 holds exactly under a linear
regression model with i.i.d. normal residuals where genotypes are scaled with unit variance.
For prior distributions of the form A : β ∼ Nm(0,Λ), where Λ is a positive semi-definite
matrix, we can use the binomial inverse theorem to find
BF =
∣∣∣∣Im + nσ2Y RΛ
∣∣∣∣−1/2 exp{− 12σ2Y Z>Λ(σ
2
Y
n
Im + RΛ)
−1Z
}
.
When Λ = τ 2ww>, wherew is scaled such thatw>Rw = 1, this expression can be simplified
by again applying the binomial inverse theorem and Sylvester’s determinant theorem. Bayes factors
for each form of prior are given in Table 4.2.
Table 4.2: Gene-Based Bayes Factors
Prior Effect Size Distribution Log Bayes Factor
Linear β ∼ Nm(0, τ
2ww>)
wherew>Rw = 1
nτ2
2σ2Y (σ
2
Y +nτ
2)
(Z>w)2 − 1
2
log
(
1 + nτ
2
σ2Y
)
Dispersed β ∼ Nm(0, 1mτ 2Im) τ
2
2mσ2Y
Z>(σ
2
Y
n
Im +
τ2
m
R)−1Z − 1
2
log
∣∣∣Im + nτ2mσ2Y R∣∣∣
Sparse βj ∼ Nm(0, δj∗,jτ
2) where
j∗ ∼ Unif{1, 2, ...,m} log
(
1
m
∑m
j=1 e
nτ2
2σ2
Y
(σ2
Y
+nτ2)
Z2j
)
− 1
2
log
(
1 + nτ
2
σ2Y
)
It is interesting to note the close relationships between these gene-based BFs and the gene-based
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test statistics described in the previous section. The linear-prior BF is a direct function of the
L-form gene-based test. Similarly, the dispersed-prior BF can be expressed as a function of a Q-form
gene-based test. Finally, the sparse-prior BF can bewritten as a function ofLSE(cZ21 , ..., cZ2m), where
the LogSumExp function LSE(x1, ..., xm) = log
(∑
j e
xj
)
is a well-known smooth approximation
to max(x1, ..., xm), and is thus closely related to the M-form gene-based test.
4.2.3 Model Fitting Algorithms and Statistical Inference
Hierarchical Bayesian Model for Gene-based Association
Here we describe a hierarchical Bayesianmodel for gene-based association. For each gene, we stratify
variants by annotation class j = 1, 2, ..., J (coding variants, eQTLs, enhancers, and UTR regions),
and further stratify variants within each class j by annotation subclass k = 1, 2, ..., Kj (tissue-type
for eQTLs and enhancers; and non-synonymous, splice-site, .... for coding variants). Let βgjk denote
the effect sizes of variants in class j and subclass k with respect to gene g, and let ξgjk denote an
indicator function such that
fβ|ξ(βgjk; ξgjk) =

fk ξgjk = 1
δ0 ξgjk = 0
where the forms of prior densities fk are given in the previous section (Table 4.2). We assume that
each gene has at most one causal class and subclass; this assumption simplifies computation, and is
analogous to an adjustedminimum p-value across stratified gene-based tests. We introduce indicator
variables θg and ξgj for each gene g and for each annotation class j, and assume
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P (θg = 1) = piθ, P (ξgj = 1|θg) =

pij θg = 1
0 θg = 0
, P (ξgjk = 1|ξgk) =

pijk ξgj = 1
0 ξgj = 0
.
In other words, θg is equal to 1 if any functional variants for gene g affect GWAS trait and 0
otherwise; ξgj is equal to 1 if any functional variants of annotation class j with respect to gene g
affect GWAS trait; and ξgjk is equal to 1 if functional variants of annotation class j and subclass k
affect GWAS trait and 0 otherwise. Under the assumption that each gene has at most one causal
annotation class and subclass, we can calculate an overall gene-based Bayes factor as
BFg =
fβˆ|θ=1(βˆg)
fβˆ|β≡0(βˆg)
=
∑
j P (ξgj = 1|θg = 1)
∑
k P (ξgjk = 1|ξgj = 1)fβˆ|ξ(βˆg|ξgjk = 1)
fβˆ|β≡0(βˆg)
=
∑
j
pij
∑
k
pijk
fβˆ|ξ(βˆg|ξgjk = 1)
fβˆ|β≡0(βˆg)
=
∑
j
pij
∑
k
pijkBFgjk,
where βˆg denotes the effect size estimates for functional variants for gene g and BFgjk :=
fβˆ|ξ(βˆg|ξgjk = 1)/fβˆ|β≡0(βˆg) has the corresponding form given in Table 4.2. We can similarly
calculate the posterior probability for annotation class j and subclass k for gene g as
P (ξgjk = 1|βˆg) = P (βˆg|ξgjk = 1)P (ξgjk = 1)
P (βˆg)
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=
P (βˆg|ξgjk = 1)P (ξgjk = 1|ξgj = 1)P (ξgj = 1|θg = 1)P (θg = 1)
P (βˆg|θg = 0)P (θg = 0) + P (βˆg|θg = 1)P (θg = 1)
=
P (βˆg |ξgjk=1)
P (βˆg |θg=0) pijkpijpiθ
(1− piθ) + P (βˆg |θg=1)P (βˆg |θg=0)piθ
=
pijpijkBFgjk
1−piθ
piθ
+BFg
,
which can be viewed as a form of Bayesian model averaging (Hoeting et al. 1999).
Algorithms for Empirical Bayes Estimation
Here, we describe algorithms to obtain empirical Bayes estimates of priorweights for each annotation
class and subclass. In general, we use E-M algorithms in which the latent variables are indicators
variables ξgjk for each gene g, annotation class j, and annotation subclass k. We estimate subclass
priors pijk separately within each annotation class j to avoid penalizing genes with association signals
across multiple annotation classes.
Within each annotation class j, we use a logistic prior of the form
P (ξgjk = 1) = 1/(1 + e
−x>gjkγ)
wherexgjk denotes an annotation vector. In the simplest case, xgjk indicates the annotation subclass
(e.g., tissue-type), and if annotation subclasses aremutually exclusive and collectively exhaustive, then
we simply have
P (ξgjk = 1) = 1/(1 + e
−γjk)
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where the intercept is omitted to avoid rank deficiency. In this case, the logisticMLE has closed form;
namely, γˆjk = logit( 1Njk
∑
g ξgjk) where Njk is the number of genes with one or more variants of
annotation class j and subclass k. Otherwise, γˆ can be estimated using Fisher scoring or gradient
descent. We note that this logistic prior does not explicitly account for interdependence between
neighboring groups of variants, and can thus be viewed as a form of composite likelihood estimation
(Varin, Reid, and Firth 2011).
Because ξgjk are unobserved, we use an E-M algorithm to estimate γˆ . In the tth E step for class j,
we update each
ξ˜
(t+1)
gjk = Eˆ
(t+1)(ξgjk|βˆgj,xgjk) = e
x>gjkγˆ
(t)
BFgjk
1 +
∑
k′ e
x>
gjk′ γˆ
(t)
BFgjk′
, k = 1, 2, ..., Kj and g = 1, 2, ..., Njk
and update γˆ(t) in the subsequent M-step using Fisher scoring or closed form (when possible) as
described previously. We then calculate subclass priors as pˆijk = Pˆ (ξgjk = 1|ξgj = 1) =
eγˆjk/
∑
k′ e
γˆjk′ .
After updating annotation subclass priors pijk , we collapse across subclasses and use the same
approach to calculate annotation class priors pij . For example, the E step becomes
ξ˜
(t+1)
gj = Eˆ(t+1)(ξgj|βˆg,xgj) =
ex
>
gj γˆ
(t)
BFgj
1 +
∑
j′ e
x>
gj′ γˆ
(t)
BFgj′
,
where BFgj =
∑
k pˆijkBFgjk. In practice, we may estimate subclass priors for annotation classes of
direct interest and use a flat prior elsewhere for convenience.
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Calculating Posterior Probabilities in Hit Regions
The composite likelihood approach described above ignores LD between neighboring genes. To
calculate gene-based posterior probabilities accounting for signals at neighboring genes, we finemap
regions with one or more marginal Bayes factors above a specified threshold. We define hit regions
by forming 1 cMwindows around each of the identified genes and merging regions that overlap. We
then calculate posterior probabilities under the assumption that each hit region contains at most one
causal gene.
4.2.4 Regulatory and Functional Annotation Data
To establish regulatory and functional relationships between variants and genes, we aggregated
annotations from four databases. To identify potentially protein-altering variants, we used
TabAnno/EPACTS ( Kang 2014). We used expression and genotype data fromGTEx to estimate eQTL
weights using forward selection and elastic net models for variable selection (GTEx Consortium
2015; Gamazon et al. 2015; Barbeira et al. 2016). To capture additional regulatory variation, we
used promoter-target pairs and enhancer-target pairs from regulatorycircuits.org inferred using
FANTOM5 CAGE data (Marbach et al. 2016), and tissue-specific enhancer-target pairs from JEME
(joint effect ofmultiple enhancers) inferred using FANTOM5andENCODE/Roadmap data (Cao et al.
2017).
Table 4.3: Functional Annotation Sources
Annotation Source Data Source Annotation Class Reference
Anno/EPACTS GENCODE, RefSeq Coding variation Kang, 2014
GTEx eQTLs GTEx eQTLs GTEx Consortium, 2015
RegulatoryCircuits FANTOM5 Enhancers, promoters Marbach et al., 2016
JEME ENCODE,FANTOM5 Enhancers Cao et al., 2017
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4.2.5 Simulation Procedures
Here, we describe procedures to simulate GWAS summary statistics using real genotype data or LD
estimates. We begin by defining summary statistics and deriving their distribution. We next outline
procedures to simulate GWAS summary statistics under the desired distribution. Finally, we describe
procedures to simulate configurations of causal genes, causal variants, and effect sizes using real
functional genomic annotation data.
GWAS Summary Statistics
In the absence of covariates, we can write the single-variant z-score test Zj for association between
genotypeGj and a continuous trait Y as
Zj = n
−1/2G˜>j Y˜ ,
where Y˜ and G˜j are scaled and centered with mean 0 and standard deviation 1. Similarly, we can
write the vector of z-scores across variants as
Z = n−1/2G˜
>
Y˜ .
Given the additive association model Yi = α0 + α>Gi + εi, we can write a scaled model Y˜ =
G˜β + ε˜, where βj = sd(Gj)αj/sd(Y ) are heritability-scale effect sizes such that β2j is equal to the
proportion of trait variance accounted for by the effect of the jth variant. Substituting this expression
for Y˜ , we can re-writeZ as
Z = n−1/2G˜
>
G˜β + n−1/2G˜
>
ε˜
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= n1/2Rβ + n−1/2G˜
>
ε˜,
where R := 1
n
G˜
>
G˜ denotes the LD matrix. If the residuals are i.i.d. normal, i.e. ε˜ ∼ N n(0, In)
where N n denotes the n-dimensional multivariate normal distribution, then the z-scores are
distributed
Z ∼ n1/2Rβ +Nm(0,R) (4.2.3)
For convenience, we define Z0 := n−1/2G˜
>
ε˜ ∼ Nm(0,R) as the z-score residual. Under the
null hypothesis that β = 0, the z-scoresZ andZ0 are equivalent.
Equation (1) also holds approximately for non-normally distributed traits, which can be shown
by asymptotic arguments under a sequence of local alternatives. For binary traits, the z-score
corresponding to the score test of association in the absence of covariates can still be written
Zj = n
−1/2G˜>j Y˜ , and Z − n1/2Rnγ d→ Nm(0,R), where γ is an effect size parameter that
depends on the odds-ratio or relative risk, minor allele frequency (MAF), population prevalence of
the trait, and the GWAS case-control ratio.
Procedures to Simulate GWAS Summary Statistics
Here, we describe procedures to simulate Z following equation (1) given a specified vector of effect
sizes β, GWAS sample size n, and LD matrix R. While the GWAS sample size n does not explicitly
appear in the distribution of the z-score residual, the rank of R and statistical precision of estimates
rjk do depend on n. Specifically, rank(R) ≤ rank(G) ≤ min(m,n), where m is the number of
variants. In addition, the number of distinct variants in a sample of size n under a neutral model
(constant population size and no selection) isO(log n); however, we ignore this dependence because
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the number of observed variants in array and imputation-based studies is fixed (restricted to variants
that are directly typed, or imputable from the reference panel). In GWAS simulations, we condition
on the reference LD structure (so that the precision of rjk estimates is irrelevant) to simulateZ with
arbitrary n given a fixed number of LD reference samples nref , and avoid rank deficiency when
necessary by LD pruning or Tikhonov regularization.
To simulate summary statistics following equation (1), we can consider two approaches:
1. Compute R1/2, simulate S ∼ Nm(0, Im), multiply to obtainZ0 = R1/2S ∼Nm(0,R), and
calculateZ = n1/2Rβ +Z0.
2. Find m × n V such that VV> = R, simulate T ∼ Nm(0, Im), multiply to obtain Z0 =
VT ∼ Nm(0,R), and calculate Z = n1/2Rβ + Z0. When reference genotypes are directly
available, we can simply take V = G˜
>
ref/
√
nref .
To simulate summary statistics for whole chromosomes (with m  n), we use Approach 2 with
reference genotypes from the European subset of the 1000 Genomes Phase 3 panel.
Simulating Configurations of Causal Genes, Variants, and Effect Sizes
To generate variant effect sizes for simulations under the alternative hypothesis, we first select K
causal annotation classes using real functional genomic annotation data described above. We then
sample Mk causal genes for each causal annotation class k = 1, 2, ...K , ensuring each that each
causal gene has at least one variant matching its causal annotation. For example, a gene with the
causal group “liver-specific eQTL” must have one or more liver-specific eVariant.
Given a configuration of causal genes and annotation groups, we simulate effect sizes for each
variant following the effect size prior forms given in Table 4.2. We then rescale βj ’s for each causal
gene to ensure that
∑
j∈Cg β
2
j = h
2
L, where Cg is the set of causal SNPs for gene g and h2L is the
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specified per-locus heritability.
4.2.6 The UK Biobank Resource
We selected 25 traits from the UK Biobank for primary analysis with effective sample size of at least
7,500, one or more significant GWAS association, and one or more relevant Mendelian gene (Table
4.4).
Table 4.4: UK Biobank: Traits Included for Primary Analysis
Phenotype Category neff No. cases No. controls
Gout Endocrine/Metabolic 12679.9 3195 404630
Hypercholesterolemia Endocrine/Metabolic 122016.0 33242 370349
Hyperlipidemia Endocrine/Metabolic 130804.5 35844 372951
Hypothyroidism NOS Endocrine/Metabolic 54687.0 14171 388068
Lipoid Metabolism Disorders Endocrine/Metabolic 131083.3 35927 373034
Mineral Metabolism Disorders Endocrine/Metabolic 8463.8 2127 406834
Overweight, Obesity & Other Hyperalimentation Endocrine/Metabolic 42695.4 10968 397993
Type 2 Diabetes Endocrine/Metabolic 72247.7 18945 387496
Angina Pectoris Circulatory System 61928.5 16175 361420
Atrial Fibrillation & Flutter Circulatory System 56983.3 14820 367697
Cardiac Dysrhythmias Circulatory System 92666.4 24681 377558
Circulatory Disease NEC Circulatory System 62782.7 16366 383215
Hypertension Circulatory System 252255.9 77977 329748
Ischemic Heart Disease Circulatory System 115780.3 31355 376600
Myocardial Infarction Circulatory System 45325.9 11703 356948
Pulmonary Heart Disease Circulatory System 16848.7 4257 400046
Muscle, Ligament, & Fascia Disorders Musculoskeletal 17726.6 4488 352949
Rheumatoid Arthritis Musculoskeletal 17412.1 4412 325621
Cholelithiasis Digestive 53215.7 13777 387430
Inguinal Hernia Digestive 61024.6 15995 330268
Psoriasis Dermatologic 8896.9 2237 389674
Breast Cancer Neoplasms 49902.8 12898 381035
Skin Cancer Neoplasms 53157.0 13752 394933
Asthma Respiratory 98301.4 26332 368381
Delirium Dementia & Amnestic & Other Cognitive Disorders Mental Disorders 7841.2 1970 397775
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4.3 Results
We first describe GaMBIT (GWAS and Multi-Omics: Bayesian Inference and Data Integration
Toolkit), an open-source software implementation of the proposed methods. Next, we evaluate
1) the Type I error rates of gene-based test statistics, 2) power and specificity to identify
tissue-specific enrichment, 3) performance identifying causal mechanisms underlying association,
and 4) performance identifying causal genes for GaMBIT and existing methods through GWAS
simulations. Finally, we discuss an application to 25 complex traits using GWAS summary statistics
from the UK Biobank. We assess 1) the empirical power of GaMBIT and existing gene-based tests
by comparing the numbers of independent genes identified at standard GWAS significance and FDR
thresholds, 2) tissue-specific enrichment across traits, and 3) concordance with known Mendelian
genes for related traits from the OMIM database using GaMBIT and existing methods.
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4.3.1 Software Implementation
Figure 4.3.1: Overview of GaMBIT Method & Workflow
GWAS Summary
Statistics
1. Annotate & Merge
Annotate single-variant summary
statistics to identify functional
coding and regulatory variants.
2. Aggregate & Calculate Tests
Aggregate variants by gene &
annotation group; calculate
multi-SNP association statistics
using LD reference data.
3. E-M Algorithm for
Tissue-Specific Priors
Estimate enrichment using
groups of regulatory variants
with tissue-specific effects.
4. Bayesian Finemapping
Update priors for groups
of regulatory variants using
tissue-specific enrichment
estimates; calculate gene-based
posterior probabilities of causation
using multi-SNP Bayes factors,
accounting for association signals
at neighboring loci.
Detailed Steps:
Legend: Input Process Output
1. Annotate & MergeFunctional
Annotations
2. Aggregate & Calculate
Tests
Stratified Multi-SNP Tests
Gene-based test statistics
stratified by functional class
and tissue
Stratified Gene-based Test Statistics
LD
Reference Data
3. E-M Algorithm for
Tissue-Specific Priors
Tissue-specific Enrichment
Tissue-specific enrichment
estimates & p-values for
eQTLs & enhancers
Tissue-specific Enrichment Estimates
4. Bayesian Finemapping
Gene Prioritization
Gene-based posterior
probabilities, stratified by
functional class
Genes by Posterior Probability at GWAS Locus
4.3.2 GWAS Simulations
We simulated 650 sets of whole-genome GWAS summary statistics following the procedures
described in Methods 4.2.5 using LD reference data from the European subset of the 1KGP Phase 3
reference panel. To evaluate Type I error rates, we simulated 500 data sets under the null hypothesis
(no genetic effects on traits). To assess the Type I error rates of eQTL enrichment statistics in the
presence of association signals, we simulated 50 data sets with 5-10 coding associations and 2-5
UTR3 associations, but no causal eQTL effects. Finally, we simulated 100 traits with 1-16 eQTL
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associations across 1-3 tissues, 2-10 coding associations, and 3-5 UTR associations. Each GWAS data
set was simulated with GWAS sample size 100,000, and each causal locus accounted for 0.05-0.10%
of trait variance.
Evaluation of Type I Error Rates using Null GWAS Simulations
We evaluated the Type I error rate of gene-and-annotation stratified gene based tests (linear
combinations of z-scores for eQTLs, and the sum of squared z-scores for other annotation classes)
and GaMBIT gene-based tests (the adjusted minimum p-value across stratified tests for each gene)
using 500 sets of whole-genome GWAS summary statistics simulated under the null hypothesis. As
expected, GaMBIT gene-based test statistics were slightly conservative due to unadjusted Bonferroni
correction. All other test statistics maintained Type I error consistent with the desired alpha level
(Table 4.5).
Table 4.5: Evaluation of Type I Error Rates in Simulations
Alpha-level Threshold
No. Reps 5e-08 1e-06 2.5e-06 5e-06 0.001 0.005 0.01 0.05
Coding 8,844,000 0 7.9e-07 3.4e-06 6.0e-06 0.00097 0.0048 0.0096 0.049
Enhancer 82,761,500 4.8e-08 1.3e-06 2.9e-06 5.8e-06 0.00100 0.0048 0.0096 0.048
Exon 8,349,000 0 1.8e-06 4.2e-06 7.4e-06 0.00105 0.0049 0.0096 0.047
Proximal 2,931,000 0 6.8e-07 2.0e-06 2.7e-06 0.00092 0.0048 0.0097 0.049
UTR3 6,757,000 0 1.9e-06 3.8e-06 7.0e-06 0.00099 0.0048 0.0095 0.048
UTR5 4,276,000 0 1.2e-06 2.8e-06 5.4e-06 0.00093 0.0048 0.0097 0.049
eQTL 167,598,000 6.0e-09 4.1e-07 1.5e-06 3.3e-06 0.00093 0.0048 0.0096 0.049
GaMBIT 16,679,000 0 5.4e-07 2.2e-06 4.3e-06 0.00079 0.0039 0.0076 0.037
Observed Type-I error rates for gene-based tests stratified by functional class and for GaMBIT gene-based tests
(adjusted minimum p-value for each gene) across 500 GWAS traits simulated under the null hypothesis (no genetic
effects on trait). Each simulated trait provides 566,350 annotation-stratified gene-based tests in total across 33,435
unique genes.
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Identifying Relevant Tissues: Sensitivity & Type I Error Rate in GWAS Simulations
We assessed Type I error and sensitivity to detect relevant tissues (tissues with one or more causal
eQTL gene for a given trait) in simulated GWAS data sets. Type I error was well controlled in null
simulations (with causal coding or UTR3 variants, but no tissue-specific effects), and relevant tissues
were detected with relatively high sensitivity in simulations with tissue-specific enrichment (Figure
4.3.2).
Figure 4.3.2: Tissue-Specific Enrichment in Simulated Data: Sensitivity & Type I Error Rate
Left: Q-Q plots of enrichment p-values for 50 null simulation replicates (no causal eQTL genes for any tissue, but causal
coding and UTR3 variants) and 100 enriched simulation replicates (1-8 causal eQTL genes for each of 1-3 tissues, as
well as causal coding and UTR3 variants at other loci).
Right: Performance identifying enriched tissues across 100 simulation replicates. Ranking of tissues within replicates is
shown in green (the quantile of 1-sided enrichment -log10 p-values within each replicate; AU-ROC=0.92 and
AU-PR=0.53), and aggregate performance is shown in red (raw 1-sided enrichment -log10 p-values across replicates;
AU-ROC=0.92 and AU-PR=0.66). The overall percentage of tissues with one or more casual eQTL gene per replicate is
4.8% (range 2.2%-6.5% across replicates).
Sensitivity to Identify Causal Mechanisms Underlying Associations in GWAS Simulations
We assessed performance identifying the causal mechanism underlying association at causal
genes (for example, liver-specific eVariants or protein-altering variants) in simulated data using
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GaMBIT’s gene-and-annotation stratified posterior probabilities (leveraging functional enrichment
to re-weight annotation-stratified statistics for each gene), posterior probabilities with a flat prior
(weighting all tissues and functional annotations equally), and p-values for gene-and-annotation
stratified test statistics. Results include 1,064 coding-effect genes (genes for which coding variants
are causal), 655 UTR3 genes (genes for which UTR3 variants are causal), and 764 eQTL genes (genes
for which eVariants are causal) across 150 simulated traits.
Overall, GaMBIT posterior probabilities had the highest sensitivity to detect causal mechanisms
(Figure 4.3.3). Posterior probabilities with flat prior had slightly higher sensitivity than GaMBIT
posterior probabilities at UTR3 genes, reflecting the smaller numbers of UTR3 genes relative to
coding-effect and eQTL genes for most simulated traits. Indeed, for simulated traits with the
strongest UTR3 enrichment (43 simulated traits for which UTR3 genes make up ≥30% of all causal
genes; a total of 185 UTR3 genes), GaMBIT outperformed flat-prior posterior probabilities at UTR3
genes (AU-ROC = 0.99, 0.98, 0.96 and AU-PR = 0.87, 0.83, 0.73 for GaMBIT, flat-prior, and p-values
respectively).
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Figure 4.3.3: ROC & PR Curves for Identifying Causal Mechanisms in Simulated Data
Receiver Operating Characteristic (ROC; top row) and Precision-Recall (PR; bottom row) curves for identifying causal
mechanisms at 2,483 causal loci across 150 simulated GWAS traits (7-25 causal loci per trait). Performance is assessed
by ranking tissue-and-annotation stratified statistics for each causal gene, where each causal gene has a single causal
annotation class (and for eQTL genes, a single causal tissue). The mean number of tissue-and-annotation stratified
statistics per causal gene is 13.8 (range 2-185; median = 11).
GaMBIT Posterior: Posterior probability that annotation class/tissue underlies association for a given gene, leveraging
tissue-specific enrichment in empirical Bayes priors (AU-ROC=0.96 and AU-PR=0.78).
Posterior with Flat Prior: Posterior probability that annotation class/tissue underlies association for a given gene,
assigning equal prior weight to each tissue and functional annotation class (AU-ROC=0.95 and AU-PR=0.72).
P-value: P-values for tissue-and-annotation stratified tests for each gene (AU-ROC=0.92 and AU-PR=0.61).
Sensitivity to Identify Causal Genes in GWAS Simulations
We assessed performance identifying causal genes at associated loci using GaMBIT gene-based test
p-values, GaMBIT gene-based posterior probabilities (leveraging functional enrichment to re-weight
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annotation-stratified statistics), gene-based posterior probabilities with a flat prior (weighting each
tissue and functional annotation class equally, but otherwise equivalent to GaMBIT posterior
probabilities), Pascal/VEGAS gene-based p-values (the sum of squared z-scores for all variants within
50 Kbp of each gene), and top-SNP-to-TSS distance (ranking each gene at a locus by the genomic
distance between its TSS and the most significant independent GWAS variant). Here, posterior
probabilities are calculated by summing across gene-and-annotation stratified posterior probabilities
for each gene. We evaluate performance for each method by ranking genes within each causal locus
(defined as the region +/- 1Mbp of a causal gene), and aggregating across all causal loci and simulated
traits.
GaMBITposterior probabilities generally provided the highest sensitivity to identify causal genes,
although flat-prior posterior probabilities had slightly higher sensitivity at UTR3 loci. Similar to
the previous section, this trend reflects UTR3 being the least-enriched annotation class for 75/150
simulated traits. For simulated traits with the strongest UTR3 enrichment (≥30% of all causal
genes have causal UTR3 variants), GaMBIT posterior had the highest performance identifying
causal genes at UTR3 loci (AU-ROC = 0.97, 0.97, 0.97, 0.81, 0.88 and AU-PR = 0.78, 0.76, 0.69,
0.20, 0.28 for GaMBIT posterior, flat-prior posterior, GaMBIT p-value, Pascal/VEGAS p-value, and
top-SNP-to-TSS distance respectively).
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Figure 4.3.4: ROC & PR Curves for Identifying Causal Genes in Simulated Data
Receiver Operating Characteristic (ROC; top row) and Precision-Recall (PR; bottom row) curves for identifying causal
genes at across 150 simulated GWAS traits with 7-25 causal loci per trait. Performance is assessed by ranking genes
within each causal locus for each trait, where a causal locus is defined as the set of genes +/- 1Mbp from a causal gene.
Further details are provided in Table 4.6.
GaMBIT Posterior: Posterior probability that a gene is causal, leveraging tissue-specific enrichment in empirical Bayes
priors.
Posterior with Flat Prior: Posterior probability that a gene is causal, assigning equal prior weight to each tissue and
functional annotation class.
GaMBIT P-value: Adjusted minimum p-value across gene-based tests stratified by tissue and functional annotation
class for each gene.
Pascal/VEGAS P-value: Annotation-agnostic SKAT p-value calculated by aggregating all variants +/- 50 Kbp from
each gene.
Top-SNP-to-TSS Distance: Distance from TSS to nearest top independent GWAS variant (most significant p-value in
sliding 2 Mbp window).
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Table 4.6: Performance Identifying Causal Genes in Simulated Data
Predictor AU-PRC AU-ROC Top-Ranked
Causal Class: cis-eVariants (765 Loci)
GaMBIT P-value 0.75 0.99 0.84
GaMBIT Posterior 0.85 0.98 0.90
Posterior with Flat Prior 0.76 0.97 0.84
Pascal/VEGAS P-value 0.17 0.77 0.35
Top-SNP-to-TSS Distance 0.18 0.81 0.28
Causal Class: Coding Variants (1,065 Loci)
GaMBIT P-value 0.68 0.96 0.80
GaMBIT Posterior 0.78 0.96 0.86
Posterior with Flat Prior 0.77 0.97 0.85
Pascal/VEGAS P-value 0.20 0.81 0.37
Top-SNP-to-TSS Distance 0.39 0.91 0.53
Causal Class: UTR3 Variants (655 Loci)
GaMBIT P-value 0.66 0.96 0.77
GaMBIT Posterior 0.72 0.97 0.80
Posterior with Flat Prior 0.75 0.97 0.83
Pascal/VEGAS P-value 0.25 0.85 0.46
Top-SNP-to-TSS Distance 0.39 0.91 0.52
Proportion of causal genes that are top-ranked within locus (defined by +/- 1Mbp of causal gene) according to each
method across 2,725 causal loci from 150 simulated traits. Leveraging tissue-specific enrichment to re-weight
associations (GaMBIT Posterior) improves performance identifying causal genes at eQTL loci by 7.6% relative to
weighting each tissue and functional class equally (Posterior with Flat Prior).
AU-ROC: Area Under Receiver Operating Characteristic (ROC) curve.
AU-PR: Area Under Precision-Recall (PR) curve.
Top-Ranked: Proportion of loci at which top-ranked gene according to method is causal.
4.3.3 Application to the UK Biobank: Analysis of 25 Complex Traits
We selected 25 traits from the UK Biobank for primary analysis with effective sample size of at least
7,500, one or more significant GWAS association, and one or more relevant Mendelian gene (Table
4.4).
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Empirical Power: Numbers of Loci Discovered Across UK Biobank Traits
We compared the numbers of significant independent loci detected for UK Biobank traits using
GaMBIT gene-based tests, Pascal/VEGAS gene-based tests, and GWAS single-variant analysis. For
GaMBIT and Pascal/VEGAS, we assessed the numbers of CCDS protein-coding genes reaching
gene-based test significance (p-value < 2.5e-6) and discovered at 5% FDR threshold, counting only
the most significant gene within a sliding 2 Mbp window. For single-variant analysis, we similarly
counted the numbers of genome-wide significant independent variants (p-value < 5e-8), including
only the most significant variant within a sliding 2 Mbp window.
Single-variant analysis identified more significant loci than either gene-based approach overall
and almost uniformly across traits. This is unsurprising, as many single-variant associations are
intergenic and not in close proximity to any protein-coding gene. Despite using fewer variants and a
higher burden ofmultiple-testing (applied at the gene level), GaMBIT detectedmore significant genes
than Pascal/VEGAS in total across traits and for each trait individually, and discovered more genes at
5% FDR than Pascal/VEGAS for 72% of all traits. This suggests that GaMBIT’s functional annotation
strategy effectively reduces noise and increases power overall, despite sacrificing a large number of
variants.
We also assessed the numbers of genes detected by using gene-and-annotation stratified
test statistics individually. GaMBIT gene-based tests (adjusted minimum p-value across
annotation-stratified statistics for each gene) consistently detected more significant independent
genes than any annotation class used individually across traits (85.6%, 17.1%, 83.3%, and 31.9% more
than gene-based tests from coding variants, enhancers, UTR variants, and eQTLs respectively). This
suggests that GaMBIT’s stratify-and-combine approach increases power overall, despite having a
higher burden of multiple testing. However, substantially more loci were discovered at 5% FDR by
applying an overall FDR adjustment across all gene-and-annotation stratified tests together rather
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than applying FDR adjustment to GaMBIT’s aggregated gene-based tests directly (Table 4.7).
Table 4.7: Empirical Power: Number of Independent Loci Discovered for UK Biobank Traits
Trait Single-Variant Pascal/VEGAS GaMBIT Stratified
Cancer
Skin cancer 35 15 (60) 25 (66) 134
Breast cancer 24 11 (34) 17 (40) 72
Endocrine/Metabolic
Hypothyroidism NOS 51 28 (159) 45 (178) 328
Type 2 diabetes 46 24 (189) 39 (185) 306
Lipoid Metabolism Disorders 37 27 (134) 32 (127) 255
Hyperlipidemia 38 27 (137) 33 (133) 254
Hypercholesterolemia 34 24 (119) 30 (124) 249
Gout 7 4 (11) 6 (13) 23
Disorders of mineral metabolism 4 2 (5) 3 (12) 38
Overweight, obesity and other hyperalimentation 9 5 (28) 7 (31) 71
Circulatory System
Ischemic Heart Disease 40 21 (133) 33 (142) 256
Myocardial infarction 21 13 (49) 18 (47) 100
Angina pectoris 20 10 (65) 19 (55) 111
Pulmonary heart disease 9 4 (5) 8 (10) 17
Atrial fibrillation and flutter 36 27 (73) 30 (82) 149
Circulatory disease NEC 6 4 (9) 6 (10) 20
Digestive
Inguinal hernia 22 13 (52) 21 (67) 128
Cholelithiasis 17 15 (48) 19 (41) 92
Musculoskeletal
Rheumatoid arthritis 6 1 (13) 5 (18) 63
Muscle, ligament, & fascia disorders 23 13 (33) 21 (34) 67
Other
Asthma 31 22 (126) 28 (122) 258
Psoriasis 7 4 (12) 6 (22) 91
Single-Variant: Number of independent genome-wide significant (p-value≤ 5× 10−8) variants.
Pascal/VEGAS: Number of significant independent genes (gene-based p-value≤ 2.5× 10−6) and number of
independent genes discovered by Pascal/VEGAS gene-based tests at 5% FDR (in parenthesis).
GaMBIT: Number of significant independent genes (gene-based p-value≤ 2.5× 10−6) and number of independent
genes discovered by GaMBIT gene-based tests at 5% FDR (in parenthesis).
Stratified: Number of independent genes discovered at 5% FDR using stratified gene-and-annotation GaMBIT test
statistics.
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Tissue-Specific Enrichment
We assessed tissue-specific eQTL enrichment across the 25 selected complex traits from the
UK Biobank. We detected strong enrichment in heart tissues for atrial fibrillation and other
cardiovascular traits, and enrichment in liver for multiple endocrine and metabolic traits (Table
4.8). However, relatively few traits exhibited significant tissue-specific enrichment overall. This may
reflect the imprecision of eQTLweights (due to the limited sample size of GTEx and imbalance across
tissues), limited statistical power (due to the limited effective sample size for many traits), polygenic
effects of small magnitude dispersed across many genes (which are less likely to be detected by
GaMBIT), or perhaps genuine genetic etiology. Here, it is also important to note that our simulations
assumed eQTL effects are measured without error, and therefore likely overestimate power to detect
enrichment in real data.
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Table 4.8: Tissue-Specific eQTL Enrichment across UK Biobank Traits
Trait Term Coef. (SE) Pval
Circulatory
Angina Pectoris Artery Aorta 1.24 (0.35) 2e-04
Liver 1.45 (0.44) 5e-04
Atrial Fib. & Flutter Heart Atrial Appendage 1.52 (0.24) 9e-11
Heart Left Ventricle 1.09 (0.28) 5e-05
Brain Cerebellar
Hemisphere
0.97 (0.36) 3e-03
Cardiac Dysrhythmias Heart Atrial Appendage 1.28 (0.35) 1e-04
Heart Left Ventricle 1.09 (0.38) 2e-03
Hypertension Artery Aorta 1.30 (0.52) 6e-03
Ischemic Heart Disease Artery Aorta 0.93 (0.26) 2e-04
Liver 1.07 (0.35) 1e-03
Myocardial Infarction Artery Aorta 0.92 (0.33) 3e-03
Liver 1.15 (0.43) 4e-03
Pulmonary Heart Disease Vagina 1.83 (0.60) 1e-03
Endocrine/Metabolic
Hypercholesterolemia Liver 0.85 (0.34) 6e-03
Overweight, Obesity, &
Other Hyperalimentation
Liver 1.20 (0.51) 9e-03
Type 2 Diabetes Liver 0.74 (0.31) 9e-03
Mental Disorders
Delirium Dementia, Adrenal Gland 5.64 (1.60) 2e-04
Amnestic, & Other Esophagus Mucosa 5.00 (1.67) 1e-03
Cognitive Disorders Nerve Tibial 4.85 (1.67) 2e-03
Brain Anterior
Cingulate Cortex BA24
5.48 (2.32) 9e-03
Musculoskeletal
Muscle, Ligament,
& Fascia Disorders
Artery Aorta 1.01 (0.38) 4e-03
Neoplasms
Breast Cancer Testis 1.38 (0.56) 7e-03
Respiratory
Asthma Prostate 0.58 (0.23) 6e-03
Liver 0.59 (0.24) 7e-03
eQTL enrichment estimates and p-values for tissues with marginally significant p-values (p < 0.01) across traits.
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Figure 4.3.5: Heatmap of Tissue-Specific Enrichment
Clustering of tissues and traits from tissue-specific enrichment estimates.
Concordance with OMIM Genes
To assess GaMBIT’s performance identifying causal genes in real data, we first extracted lists of
known Mendelian genes for related traits the OMIM database for each of the 25 UK Biobank traits.
We next filtered the lists of OMIM genes, retaining only genes within 1 Mbp of a significant GWAS
association (single-variant p-value < 5e-8) or a significant gene-based test (Pascal/VEGAS orGaMBIT
p-value < 2.5e-6) for the corresponding UK Biobank trait. After filtering, we retained 55 unique
OMIM genes across traits from the original list of 353 unique genes.
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Figure 4.3.6: ROC and PR Curves for OMIM Genes in the UK Biobank
Receiver Operating Characteristic (ROC; left) and Precision-Recall (PR; right) curves for 55 OMIM genes in total across
25 traits in the UK Biobank. Only OMIM genes within +/- 1 Mbp of a genome-wide significant association (p-value<
5e-8) or significant Pascal/VEGAS or GaMBIT gene-based test (p-value< 2.5e-6) are included (55 OMIM genes from a
total of 404). Performance is assessed by ranking genes within each OMIM locus for each trait, where an OMIM locus is
defined as the set of genes +/- 1Mbp from an OMIM gene.
GaMBIT Posterior: Posterior probability that gene causal (AU-ROC=0.87, AU-PR=0.41).
GaMBIT P-value: Adjusted minimum p-value across gene-based tests stratified by tissue and functional annotation
class for each gene (AU-ROC=0.86, AU-PR=0.44).
Pascal/VEGAS P-value: Annotation-agnostic SKAT p-value calculated by aggregating all variants +/- 50 Kbp from
each gene (AU-ROC=0.85, AU-PR=0.26).
Top-SNP-to-TSS Distance: Distance from TSS to nearest top independent GWAS variant (most significant p-value in
sliding 2 Mbp window) (AU-ROC=0.85, AU-PR=0.42).
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Table 4.9: Concordance at OMIM Loci in UK Biobank Data: Quantile Rank of OMIM Genes
Mean Locus Quantile Rank of OMIM Genes for:
GaMBIT Top SNP to Pascal/VEGAS No.
Trait Category Post. Pr. P-value TSS Dist. P-value Genes
Neoplasms 0.83 0.83 0.73 0.74 8
Endocrine/metabolic 0.90 0.87 0.90 0.88 26
Circulatory System 0.91 0.88 0.96 0.82 7
Respiratory 0.88 0.67 0.77 0.86 3
Digestive 0.97 1.00 1.00 0.70 3
Dermatologic 0.75 0.76 0.72 0.71 3
Musculoskeletal 0.64 0.75 0.42 0.73 5
Overall 0.86 0.84 0.83 0.82 55
Average quantile of OMIM genes within each locus (+/- 1Mbp of each OMIM gene) across traits in each category for
each method. Quantiles of OMIM genes that appear for multiple traits in a given category are first averaged across traits
so that each OMIM gene contributes equally to the total. The average quantile of OMIM genes is approximately equal
to AU-ROC.
Table 4.10: Concordance at OMIM Genes in UK Biobank Data: Proportion of Top-Ranked OMIM
Genes
Proportion of Top-Ranked OMIM Genes for:
GaMBIT Top SNP to Pascal/VEGAS No.
Trait Category Post. Pr. P-value TSS Dist. P-value Genes
Neoplasms 0.50 0.62 0.25 0.25 8
Endocrine/metabolic 0.64 0.65 0.62 0.62 26
Circulatory System 0.57 0.43 0.71 0.29 7
Respiratory 0.33 0.33 0.33 0.33 3
Digestive 0.67 1.00 1.00 0.67 3
Dermatologic 0.33 0.00 0.33 0.33 3
Musculoskeletal 0.20 0.40 0.20 0.00 5
Overall 0.54 0.56 0.53 0.44 55
Proportion of OMIM genes that are top-ranked within each locus (+/- 1Mbp of each OMIM gene) across traits in each
category for each method. For OMIM genes that correspond with multiple traits, proportions are averaged across traits
within each category.
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4.4 Discussion
Here, we described novel Bayesianmethods to identify likely causal genes, pathways, andmechanisms
underlying GWAS associations. We also outlined our efforts to assemble a comprehensive
compendium of gene-centric regulatory and functional annotations by aggregating databases derived
from Roadmap/ENCODE (Cao et al. 2017; Bernstein et al. 2010; ENCODE Project Consortium
2012), FANTOM5 (Marbach et al. 2016; Cao et al. 2017; Lizio et al. 2015), and GTEx (GTEx
Consortium 2015; Gamazon et al. 2015; Barbeira et al. 2016). To apply our approach with GWAS
summary statistics, we used our approach described Chapter 2 to estimate LD from reference
panels on-the-fly for gene-based association statistics. Finally, we presented a novel, open-source
computational toolkit, GaMBIT, that allows researchers to simultaneously examine a range of
potential regulatory and functional perterbations underlying GWAS association signals, and permits
both Frequentist and Bayesian inference.
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4.6 Appendix: Supplementary Tables & Figures
Supplementary Table 4.1: Ranking Genes at OMIM Loci for UK Biobank Traits
GaMBIT Top SNP to Pascal/VEGAS No.
Gene Post. Pr. P-value TSS Dist. P-value Traits
Neoplasms CDKN2A 0.86 0.90 0.95 0.95 1
CDSN 0.77 0.64 0.13 0.79 1
IRF4 1.00 1.00 1.00 1.00 1
MC1R 1.00 1.00 0.96 0.25 1
SLC45A2 1.00 1.00 1.00 0.82 1
TUBB 0.09 0.12 0.49 0.25 1
TYR 1.00 1.00 0.89 1.00 1
CHEK2 0.95 1.00 0.40 0.85 1
Endocrine/metabolic ABCC8 0.91 0.91 0.95 0.86 1
GCKR 1.00 0.89 1.00 0.84 1
HNF1A 1.00 1.00 0.97 1.00 1
HNF1B 0.96 1.00 1.00 0.83 1
IGF2BP2 1.00 1.00 0.94 1.00 1
INS 0.84 0.23 0.55 0.65 1
INSR 0.94 0.74 0.49 0.83 1
IRS1 1.00 1.00 1.00 0.44 1
KCNJ11 1.00 1.00 1.00 1.00 1
MTNR1B 1.00 1.00 1.00 1.00 1
RETN 0.13 0.29 0.67 0.58 1
SLC30A8 1.00 1.00 1.00 1.00 1
TCF7L2 1.00 1.00 1.00 1.00 1
WFS1 1.00 1.00 1.00 1.00 1
APOB 1.00 1.00 1.00 1.00 3
HMGCR 0.92 1.00 1.00 1.00 3
LDLR 1.00 1.00 1.00 1.00 3
LIPC 1.00 1.00 1.00 1.00 3
LPL 1.00 1.00 1.00 1.00 3
PCSK9 1.00 1.00 1.00 1.00 3
SCARB1 1.00 1.00 1.00 1.00 3
SORT1 0.99 0.97 0.93 1.00 3
LDLRAP1 0.03 0.06 0.30 0.08 2
DYRK1B 0.66 0.50 0.68 0.70 1
SLC17A3 0.94 0.96 0.98 0.98 1
MC4R 1.00 1.00 1.00 1.00 1
Circulatory System APOE 1.00 1.00 1.00 1.00 1
MMP3 0.83 0.77 0.81 0.19 3
NOS3 0.60 0.71 1.00 0.97 1
MYH6 1.00 1.00 1.00 0.97 2
NKX2-5 1.00 1.00 1.00 1.00 1
SCN5A 0.92 0.88 0.92 0.96 1
TAB2 1.00 0.78 1.00 0.67 1
Respiratory CHI3L1 0.93 0.96 0.93 0.86 1
IL13 1.00 1.00 1.00 1.00 1
TNF 0.71 0.03 0.39 0.73 1
Digestive ABCB4 0.92 1.00 1.00 1.00 1
ABCG8 1.00 1.00 1.00 1.00 1
SLC10A2 1.00 1.00 1.00 0.11 1
Dermatologic HLA-C 0.99 0.92 0.99 0.33 1
PSMB8 0.25 0.45 0.16 0.81 1
TRAF3IP2 1.00 0.92 1.00 1.00 1
Musculoskeletal LTA 0.38 0.72 0.02 0.72 1
NFKBIL1 0.38 0.72 0.03 0.71 1
PTPN22 1.00 1.00 1.00 0.84 1
IL10 0.96 1.00 0.64 0.84 1
PLEC 0.49 0.32 0.42 0.53 1
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Supplementary Table 4.2: OMIM Genes & Traits Used for Analysis of UK Biobank Traits
Gene OMIM Traits UK Biobank Traits Detected
MMP3 Coronary Heart Disease Angina Pectoris; Cardiovascular Traits GWAS
CHI3L1 Asthma-related Traits Asthma GWAS
IL13 Asthma Asthma GWAS,Pascal,GaMBIT
TNF Asthma; Dementia Asthma; Delirium Dementia Pascal
MYH6 Atrial Septal Defect Atrial Fibrillation; Cardiac Dysrhythmias Pascal,GaMBIT
NKX2-5 Atrial Septal Defect; Heart Malformations; Hypothyroidism Cardiovascular Traits Pascal,GaMBIT
CHEK2 Breast And Colorectal Cancer; Breast Cancer Breast Cancer; Skin Cancer GaMBIT
ABCB4 Gallbladder Disease Cholelithiasis GWAS,Pascal,GaMBIT
ABCG8 Gallbladder Disease Cholelithiasis GWAS,Pascal,GaMBIT
SLC10A2 Bile Acid Malabsorption Cholelithiasis GaMBIT
APOB Hypercholesterolemia Lipid Traits GWAS,Pascal,GaMBIT
HMGCR LDL Level Qtl 3; Statins Lipid Traits GWAS,Pascal,GaMBIT
LDLR Hypercholesterolemia; Ldl Cholesterol Level Qtl2 Lipid Traits GWAS,Pascal,GaMBIT
PCSK9 Hypercholesterolemia; LDL Level Qtl Lipid Traits GWAS,Pascal,GaMBIT
SCARB1 HDL Level Qtl6 Lipid Traits GWAS,GaMBIT
SORT1 LDL Level Qtl6 Lipid Traits GWAS,Pascal,GaMBIT
LIPC T2D; HDL Level Qtl 12 Lipid Traits; Type 2 Diabetes GaMBIT
LPL Combined Hyperlipidemia; HDL Level Qtl 11 Lipid Traits; Type 2 Diabetes Pascal,GaMBIT
PLEC Muscular Dystrophy Muscle/Ligament Disorders GWAS
NFKBIL1 Rheumatoid Arthritis Muscle/Ligament Disorders; Gout; Rheumatoid Arthritis Pascal,GaMBIT
PTPN22 Diabetes; Rheumatoid Arthritis Musculoskeletal Traits; Type 2 Diabetes GaMBIT
SLC17A3 Gout Susceptibility Gout GWAS,GaMBIT
LTA Myocardial Infarction; Psoriatic Arthritis Gout; Myocardial Infarction; Rheumatoid Arthritis Pascal,GaMBIT
APOE Coronary Artery Disease Ischemic Heart Disease GWAS,Pascal,GaMBIT
NOS3 Coronary Artery Spasm 1; Hypertension; Ischemic Stroke Ischemic Heart Disease GWAS
IRS1 Coronary Artery Disease; T2D Ischemic Heart Disease; Type 2 Diabetes GWAS,GaMBIT
IRS1 Coronary Artery Disease; T2D Ischemic Heart Disease; Type 2 Diabetes GWAS
MC4R Obesity Overweight, Obesity GWAS,GaMBIT
HLA-C Psoriasis Susceptibility Psoriasis GWAS,Pascal,GaMBIT
PSMB8 Autoinflammation Psoriasis GWAS,Pascal
TRAF3IP2 Psoriasis Susceptibility Psoriasis GWAS,Pascal,GaMBIT
MC1R Uv-induced Skin Damage Psoriasis; Skin Cancer GWAS,Pascal,GaMBIT
MC1R Uv-induced Skin Damage Psoriasis; Skin Cancer GWAS
CDKN2A Pancreatic Cancer/melanoma Syndrome Skin Cancer GWAS,Pascal
CDSN Peeling Skin Syndrome Skin Cancer GWAS
IRF4 Skin/hair/eye Pigmentation Skin Cancer GWAS,Pascal,GaMBIT
SLC45A2 Skin/hair/eye Pigmentation 5 Skin Cancer GWAS,GaMBIT
TUBB Symmetric Circumferential Skin Creases Skin Cancer GWAS
TYR Skin/hair/eye Pigmentation 3 Skin Cancer GWAS,Pascal,GaMBIT
ABCC8 T2D; Hyperinsulinemic Hypoglycemia Type 2 Diabetes GWAS,GaMBIT
GCKR Fasting Plasma Glucose Level Qtl 5 Type 2 Diabetes GWAS,Pascal
HNF1A T2D Type 2 Diabetes GaMBIT
HNF1B T2D; Renal Cysts And Diabetes Syndrome Type 2 Diabetes GWAS
IGF2BP2 T2D Type 2 Diabetes GWAS,Pascal,GaMBIT
INS T2D; Hyperproinsulinemia; MODY Type 2 Diabetes GWAS
INSR T2D; Hyperinsulinemic Hypoglycemia Type 2 Diabetes GWAS
KCNJ11 Diabetes; T2D; Hyperinsulinemic Hypoglycemia; MODY Type 2 Diabetes GWAS,GaMBIT
MTNR1B T2D Type 2 Diabetes GWAS,Pascal
RETN T2D; Hypertension Type 2 Diabetes GWAS
SLC30A8 T2D Type 2 Diabetes GWAS,GaMBIT
TCF7L2 T2D Type 2 Diabetes GWAS,Pascal,GaMBIT
WFS1 T2D Type 2 Diabetes GWAS,GaMBIT
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Chapter 5
Discussion
5.1 Summary
In this dissertation, we assessed strategies to improve imputation and statistical power for GWAS of
populations that are underrepresented in current imputation reference panels, presented methods to
expedite LD computationswith increasingly large sample sizes, and developed a statistical framework
to identify likely causal genes and mechanisms in post-GWAS analysis leveraging expanding
regulatory genomic annotation data. Here, we review these works, discuss their limitations and
prospects in the ever-evolving landscape of human genomics, and suggest possible directions for
future research.
5.2 Sequencing & Imputation in the Age of Massive Reference
Panels
In Chapter 2, we assessed sequencing-and-imputation as a strategy to improve genotype imputation
and increase power in GWAS populations that are underrepresented in current imputation reference
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panels. While imputation reference panels have increased in size since the release of the 1KGP, they
have not always increased in diversity. The largest current imputation reference panels, e.g. HRC
and UK10K (UK10K Consortium 2015; McCarthy et al. 2016), are predominantly European, and
provide limited imputation quality in non-European, admixed, and isolate populations (Deelen et al.
2014; Lencz et al. 2017). For these populations, we found that sequencing a subset of participants can
substantially increase genomic coverage and power to detect association.
Sequencing to construct augmented or population-specific reference panels is expected to be
most impactful for populations that are least represented in current imputation reference panels
(Van Leeuwen et al. 2015; Roshyara and Scholz 2015). By contrast, our analysis in Chapter 2 was
limited to four populations in which relatively large sequencing studies have already been conducted
(African Americans, Latino Americans, Sardinians, and Finns). However, we are hopeful that our
results can serve as a guidepost for the design and planning of GWAS in other populations with
comparable demographic histories but more limited representation in current imputation reference
panels.
With larger and more representative imputation reference panels, array-and-imputation based
genotyping provides a closer approximation to genotyping by deep sequencing. Forthcoming
reference panels, e.g. from the TOPMed WGS Program (NHLBI TOPMed WGS 2018), are
substantially larger and more diverse than the HRC. These resources will allow far more accurate
and comprehensive imputation for a wider range of populations, so that imputation coverage and
accuracy more closely approximate WGS, thereby lessening the utility of study-specific sequencing
for many populations and traits. However, the utility of sequencing and imputation for extreme
genetic architectures is less clear; e.g., de novo mutations cannot be imputed regardless of reference
panel size. Thus, the efficacy of population-based sequencing and imputation studies, family-based
studies, and other strategies under extreme genetic architectures is an area for further research.
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Finally, individual-level genotype data are not publicly available for many of the largest
imputation reference panels, e.g. the HRC and UK10K, which must be accessed indirectly through
imputation servers (UK10K Consortium 2015; McCarthy et al. 2016). Thus, direct augmentation
with other reference panels, e.g. study-specific reference data, is often difficult or impossible.
Other strategies to combine results from multiple reference panels include meta-imputation, which
strategically combines results from multiple reference panels (Sayantan Das 2017), and a distributed
reference panel approach, in which sets of imputed dosages from multiple reference panels are
combined for association analysis (Zhou et al. 2017). A more comprehensive evaluation of these
and other strategies to indirectly combine multiple reference panels, as well as tools to facilitate
analysis with multiple reference panels (e.g., on imputation servers), will be important for future
sequencing-and-imputation studies.
5.3 Efficient Computation with Human Genetic Data
In Chapter 3, we developed efficient methods to estimate linkage disequilibrium (LD) with large
sample sizes, exploiting the natural sparsity and high redundancy of genetic data to increase
computational efficiency. Efficient methods to calculate LD will be critical for the analysis of
GWAS summary statistics with large sample sizes, which will require correspondingly precise and
comprehensive LD estimates, including for rare and low-frequency variants (Benner, Havulinna, et al.
2017). In addition, because individual-level genotype data are not publicly available for many of the
largest WGS datasets (e.g., McCarthy et al. 2016; NHLBI TOPMed WGS 2018), the development of
web-based utilities for querying LDwithout compromising genetic privacywill be important to allow
researchers to utilize these resources for analyses involving LD (Quick et al. 2018).
One area for further research in this domain is the development of compressed data formats
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that allow efficient LD querying and estimation while avoiding quadratic storage costs, and do not
compromise genetic privacy. In addition, sparsity and haplotype structure can be used to improve
efficiency in a variety of other contexts; e.g., compact genotype data formats (e.g., M3VCF format;
Das and Abecasis 2015; Sayantan Das et al. 2016), and efficient computation for routine tasks and
analyses (e.g., sparse representations have been used to efficiently calculate single-variant association
tests; Dey et al. 2017).
5.4 Post-GWASMethods for the Omics Age
In Chapter 4, we developed an integrative Bayesian model and software toolkit, GaMBIT, to identify
causitive genes, pathways, and biological mechanisms underlying GWAS associations by leveraging
regulatory and functional genomics databases. We demonstrated through simulations that GaMBIT
has high precision to identify causal genes and mechanisms given accurate and comprehensive
functional genomic annotations. However, despite substantial progress in regulatory genomics,
current functional genomic annotations remain incomplete and often imprecise (Bodea et al. 2018;
e.g., GTEx sample sizes are limited and imbalanced across tissues [GTEx Consortium 2015; Hao
et al. 2018]). Thus, we expect the utility of the proposed methods to increase as functional genomic
annotations improve through new technologies and larger studies. In particular, improved methods
to infer relationships between regulatory elements and target genes will be important to facilitate the
interpretation of non-coding associations (Marbach et al. 2016).
Despite the imprecision of current annotation data, our analysis of 25 traits using GWAS
summary association statistics from the UK Biobank identified biologically relevant tissues and
showed high concordance with known Mendelian genes. We also demonstrated that LD and
pleiotropy can confound gene-based tests, and showed that our framework can providemore reliable
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and interpretable gene-based analysis by accounting for multiple possible mechanisms underlying
association. Finally, we found that our aggregated annotation-stratified gene-based testing approach
has substantially higher power than annotation-agnostic gene-based tests and any individual class of
annotation-stratified gene-based test (e.g., TWAS/PrediXcan tests across one or more tissues, Gusev
et al. 2016; Gamazon et al. 2015).
GaMBIT’s core methods involve a number of simplifying assumptions, which could be relaxed in
a variety of possible extensions and generalizations. For example, GaMBIT’s Bayesianmodel assumes
that each GWAS association region harbors at most one causal gene and annotation class. This
assumption primarily serves to simplify computation, as the number of possible causal configurations
is exponential in the number of genes and annotation classes. However, a variety of approaches
have been used to effectively reduce the search space over causal configurations in single-variant
fine-mapping (e.g., Wen et al. 2016; Benner, Spencer, et al. 2016), which could also be adapted in the
proposed framework.
Another natural extension of the GaMBIT framework is to incorporate gene-based annotations,
e.g. biological pathways and molecular functions, to improve gene prioritization and detect gene-set
enrichment. Gene-based annotations can be incorporated by introducing an additional logistic prior
at the gene level, similar in form to the priors used for annotation-stratified gene-based associations.
This extension will be explored in a forthcoming work.
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